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Natural killer (NK) cells are implicated in tumour surveillance and control in a 
number of settings. The liver contains large numbers of NK cells and 
hepatocellular carcinoma (HCC) has been shown to express various ligands 
that permit interactions with NK cells, some of which have been shown to 
have prognostic significance. Similar prognostic associations have been 
shown for colorectal cancer, a tumour which commonly metastasizes to the 
liver. However the mechanistic underpinning of these effects is unclear. 
This thesis describes a survey of soluble NKG2D ligand expression in 
patients with HCC caused by chronic hepatitis B (CHB), patients with CHB 
without cancer, and healthy controls. ULBP1 was found to be raised in HCC 
patients; where it was associated with poor survival, and in active CHB; 
where it was associated with hepatitis B viral load. ULBP1 was not seen in 
secondary liver tumours, suggesting that this protein may be useful as a 
biomarker of severe disease or to monitor treatment response. The other 
NKG2D ligands MICA, MICB, ULBP2 and ULBP3 were not found to be 
elevated in patient serum. Soluble NKG2D ligands did not affect NKG2D 
expression by circulating NK cells. 
Tumour infiltrating NK cells have the potential to be important effector cells, 
but are functionally defective. This work builds on recent advances in the 
understanding of liver-resident NK cells to characterise the functional defect 
in primary and secondary liver cancers, using human ex vivo intrahepatic and 
tumour-infiltrating NK cells. Using an in vitro model of HCC we have 
investigated the mechanisms for this defect and examine the potential for IL-
15 to restore NK cell cytotoxicity and cytokine production. Ex-vivo tumour-
infiltrating NK cells had reduced NKG2D expression, IFNγ production and 
degranulation potential compared with paired intrahepatic NK cells, but 
maintained expression of NKp46. We were able to recapitulate this 
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phenotype by co-culture with an HCC cell line, but were not able to protect 
NK cells from NKG2D downregulation and functional inhibition by NKG2D 
blockade. However, IL-15 was able to restore function after HCC exposure. 
This model may serve as an in-vitro assay for future therapeutics targeting 




Hepatocellular carcinoma (HCC) is the third largest cause of cancer death in 
humans, responsible for over 750,000 deaths annually. The conventional 
cancer treatment modalities are largely ineffective in this disease. Surgical 
cure is possible, but only where HCC is diagnosed early, which is rare. 
Cytotoxic chemotherapy is ineffective, as is radiotherapy. Sorafenib, the 
single licensed drug for HCC can extend life for 2-3 months, but does not 
induce objective responses. 
Recent advances in immunotherapy have shown promise in HCC. Blockade 
of programmed-death 1 (PD1) allows T cells to respond to tumours, and in 
HCC has shown 20% response rates. We have explored interactions 
between HCC and natural killer (NK) cells, a lymphocyte present in large 
numbers in the liver, in an attempt to engage their cytotoxic potential against 
HCC. 
Patients with HCC were found to have elevated circulating levels of ULBP1, a 
ligand for the activating NK cell receptor NKG2D. This protein did not affect 
circulating NK cells, but was associated with poor prognosis in HCC. This 
finding could be utilised clinically either to screen for HCC in at-risk patients, 
or as a prognostic marker in HCC. It might also be important in the selection 
of future immunotherapies, as NK cells transfected with NKG2D chimeric 
antigen receptors are currently being investigated for HCC, and the 
circulating NKG2D ligand environment may be an important consideration in 
selecting personalized treatment. 
Unexpectedly, circulating ULBP1 was also found in patients with chronic 
hepatitis B that required treatment. There is a need in low-middle income 
countries for a simple, inexpensive test that can substitute for the current, 
expensive and poorly available investigations required to assess individuals 
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with hepatitis B infection. Development of the current ELISA into a lateral-
flow assay might greatly improve access to hepatitis B assessment and 
therefore treatment – a key goal of the 2016 WHO global strategy for viral 
hepatitis. 
We have also examined the phenotype and function of NK cells in liver 
tumours and healthy liver tissue from the same donors, and using a 
hepatocellular carcinoma cell line have been able to model the inactivation of 
human intrahepatic NK cells interacting with HCC. This platform allows the 
testing of potential drugs to re-activate NK cell anti-tumour function. IL-15 is 
one such agent, and modified or targeted forms of IL-15 could be rapidly 
tested in this model before progressing to animal models or human trials. The 
activity of other classes of drugs, such as receptor blocking antibodies, can 
also be tested in this model.  
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Chapter 1 Introduction 
1.1 Biology of Natural Killer cells 
Natural Killer (NK) cells, so called because of their ability to display 
cytotoxicity without prior sensitisation (natural killing), are innate lymphocytes 
present in blood and other tissues (Kiessling et al. 1975; Caligiuri 2008; Spits 
et al. 2013; Eberl et al. 2015). Like other lymphocytes they are derived from 
CD34+ haematopoietic precursor cells (HPC), predominantly from the bone 
marrow (Di Santo 2006), although CD34+ precursors giving rise to NK cells 
have been seen in secondary lymphoid tissue including thymus and gut-
associated lymphoid tissue, peripheral blood, cord blood and decidua (Vacca 
et al. 2006; Bozzano et al. 2017). Within the last 10 years it has become 
apparent that NK cells are a subset of the innate lymphoid cells (ILCs) (Spits 
et al. 2016; Klose & Artis 2016). There are believed to be five major ILC 
populations, which arise from the same common lymphoid precursor and 
share canonical transcription factors and cytokine production with T cell 
populations: NK cells driven by Eomes and secreting IFNγ are analogous to 
CD8 T cells; ILC1 cells driven by T-bet and secreting IFNγ are analogous to 
CD4 TH1 T cells; ILC2 cells driven by GATA-3 and secreting IL-4, IL-5 and IL-
13 are analogous to CD4 TH2 T cells; and two populations of ILC3 cells 
(differentiated by their expression of NKp46) driven by RORγt and secreting 
IL-17 and IL-22 are analogues of CD4 TH17 and TH22 T cells (Eberl et al. 
2015). As might be implied by this classification, the ILCs are 
developmentally distinct from NK cells, arising from the common helper 
innate lymphoid progenitor (CHILP), as a first stage in differentiation from the 
early innate lymphoid progenitor (Zook & Kee 2016). However, murine ILC1 
precursors are indistinguishable from NK cell precursors without fate 
mapping of the transcription factor PZLF (Constantinides et al. 2015). Mature 
ILCs are CD3 negative lymphocytes residing in tissues, are CD127 (IL7 
receptor α) positive and do not express CD56 (Spits et al. 2016). In mice, 
fate mapping studies have demonstrated that there is plasticity of ILC 
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phenotypes, with IL-12 able to induce transdifferentiation of both ILC2s and 
ILC3s into ILC1 cells (Vonarbourg et al. 2010; Ohne et al. 2016; Lim et al. 
2016). Conversely, ILC1s can be induced to transdifferentiate into ILC2s in 
response to IL-4 and into ILC3 cells in response to IL1β and IL-23 (Bal et al. 
2016; Bernink et al. 2015). NK cells and ILC1 cells have some similarities, 
particularly in mice where they are both NK1.1+, NKp46+ cells that secrete 
IFNγ. ILC1s have important roles in colitis, both infectious and inflammatory 
(Abt et al. 2015; Buonocore et al. 2010; Bernink et al. 2013). ILCs may have 
important roles in responses to cancer. ILC1-like cells have been seen in a 
murine cancer model, although their specific role remains unclear (Dadi et al. 
2016). In cultures of tumour-infiltrating lymphocytes expanded with high 
doses of IL-2, an innate lymphoid population suppressed anti-tumour T cell 
proliferation and had a transcriptional profile overlapping with ILCs and NK 
cells (Crome et al. 2017). Whether there is an in-vivo equivalent of this cell 
remains uncertain. 
A five-stage process of NK cell maturation has been proposed (Freud et al. 
2014) (Figure 1.1), giving rise to CD56bright (stage 4) and CD56dim (stage 
5) NK cells in the periphery. However, recent work suggests that an 
alternative, transcriptionally distinct, CD34+ precursor may leave the bone 
marrow and differentiate directly into mature NK cells (and T cells) in the 
periphery in the setting of inflammatory disease, bypassing the maturation 
that traditionally occurs in the lymph node (Bozzano et al. 2015). It may be 
that phenotypically similar NK cells can arise from different developmental 
pathways (Bozzano et al. 2017). IL-15 is considered the most important 
cytokine in NK homeostasis. It promotes NK cell differentiation, proliferation 
and survival (Carson, Giri, Lindemann, Linett, Ahdieh, Paxton, Anderson, 
Eisenmann, Grabstein & Caligiuri 1994a; Carson et al. 1997; Mrózek et al. 
1996). Expression of CD122, the beta chain shared by the IL-2 and IL-15 
receptors in stages 2-3, allows immature NK cells to respond to IL-15, 
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Figure 1.1  Schematic of NK cell development.
Adapted from Freud et. al. 2014. NK cells arise from the common lymphoid progenitor in the 
bone marrow. Early stages of NK cell development occur in the bone marrow, and are 
associated wth the expression and then loss of CD34. The final stages of NK cell develop-
ment may occur in lymphoid tissue or in the peripheral blood. In the final stage of develop-
ment NK cells express CD16, the Fc gamma receptor III that is responsible for antibody 
dependent cell cytotoxicity.
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CD56bright NK cells (Freud et al. 2005; Mrózek et al. 1996; Mattei et al. 
2001).  
Both CD56bright and CD56dim NK cells may be found in peripheral blood 
and other tissues (Björkström et al. 2016). Their activity is determined by a 
range of germline-encoded receptors that give activatory and inhibitory  
signals (Long et al. 2013). The balance of these signals determines 
activation, leading to the major effector functions of cytotoxicity by release of 
lytic granules containing perforin and granzymes, and production of the 
inflammatory cytokines interferon gamma (IFNγ) and tumour necrosis factor 
alpha (TNFα), as well as ligation of death receptors by expression of death 
ligands such as TRAIL (Lanier 2008b). The expression of each of the various 
NK cell receptors produces remarkable phenotypic diversity among the NK 
cell population that is only beginning to be understood (Horowitz et al. 2013). 
NK cell activatory and inhibitory receptors and their ligands are species-
specific, and many have undergone rapid evolution (Parham & Moffett 2013; 
Carrillo-Bustamante et al. 2016). The human NK cell receptors and their 
ligands are shown below (Figure 1.2). The ligands of some receptors remain 
unknown, the most recent discovery is the ligand for NKp46, shown to be 
properdin, or complement factor P (Narni-Mancinelli et al. 2017). These 
receptor-ligand interactions occur in a highly organised structure known as 
the immune synapse (Davis et al. 1999). Contact, granule polarisation, and 
degranulation are complex processes requiring multiple signals, typically an 
adhesion signal via the integrin LFA1 and an activatory signal via the 
antibody-dependent cell cytotoxicity (ADCC) receptor CD16, or other 
activatory receptors such as NKG2D, 2B4 or NKp46, often in concert 
(Bryceson et al. 2006). Super-resolution imaging of the immune synapse and 
underlying cytoskeletal remodelling has shown that different activating 
receptors have different potency, for example that NKp46 is unable to 
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Activating receptors Inhibitory receptors
Adhesion receptors
Figure 1.2 Summary of the human NK cell receptor repertoire. Adapted 
from Vivier et. al.  2008 and Vivier et. al. 2011. Tables to illustrate the NK 
cell receptors available for cell-cell contacts. These lists are not exhaustive 
and cytokine and chemokine receptors are not depicted. BAT3, HLA-B-
associated transcript 3; AICL, activation-induced C-type lectin; DNAM-1 
(also known as CD226), DNAX Accessory Molecule-1; PVR (also known as 
CD155), poliovirus receptor; CRACC, CD2-like receptor-activating cytotoxic 
cell; KIR, killer immunoglobulin-like receptors; LAIR, Leukocyte-associated 
immunoglobulin-like receptor; KLRG1, killer cell lectin-like receptor G1; 
SIGLEC, sialic acid binding immunoglobulin-like lectins; LILRB1, Leukocyte 
immunoglobulin-like receptor subfamily B member 1; TIGIT, T cell 
immunoreceptor with immunoglobulin and ITIM domains; VCAM, vascular 
cell adhesion molecule; ICAM, intercellular adhesion molecule. 
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signal provided via LFA1, whereas NKG2D or CD16 signalling alone is able 
to induce actin rearrangement (A. C. N. Brown et al. 2012). 
As well as responding to ligands expressed on cell surfaces, NK cell activity 
is modulated by a number of cytokines. The related cytokines IL-2 and IL-15 
are important in NK cell homeostasis. IL-2 induces NK cell proliferation  
(T. K. Yu et al. 2000; Warren et al. 1996), and at high levels can be used to 
generate lymphokine-activated killer cells (LAK), which have been used in 
early cancer immunotherapy (Rosenberg et al. 1985). IL-12 is the most 
important signal driving production of IFNγ, usually supplemented by 
additional signals, such as IL-1, IL-2, IL-15, IL-18, or CD16 or NKG2D 
engagement (Parihar et al. 2002; Ferlazzo et al. 2004; Caligiuri 2008). The 
combination of T cell-derived IL-2 and IL-12, produced by dendritic cells and 
cells of the monocyte/macrophage lineage, is a potent stimulus for IFNγ 
production, which in turn activates antigen presenting cells (APC). IL-12, IL-
15 and IL-18 also antagonise the inhibitory effect of transforming growth 
factor beta (TGF-β) (J. Yu et al. 2006). IL-15 also drives cytotoxicity, and in 
mice can contribute to anti-tumour immunity (Sutherland 2006). 
Killer immunoglobulin-like receptors provide an important control on NK cell 
function and are a major mechanism by which “missing self” behaviour is 
generated. A key feature of this system is diversity of both receptors and their 
HLA class I ligands, across species, individuals, cells and genes (Parham & 
Moffett 2013). Simian primates have diversified KIR genes from the founder 
gene KIR3DL, whereas cattle have an independent KIR system diversified 
from KIR3DX, which is inactive in simians (Guethlein et al. 2007). Mice use a 
diversified set of LY49 receptors, a genetically distinct set of molecules 
related to calcium-dependent lectins, which bind a separate site on MHC 
class I molecules (Natarajan et al. 2002). In humans there are three lineages 
of KIRs that bind HLA class I, lineage I KIRs bind HLA-G, lineage II KIRs bind 
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the A3/11 epitope of HLA-A or the Bw4 epitope of HLA-A and HLA-B. lineage 
III KIRs bind either the C1 or C2 epitopes of HLA-C. The KIR genes are 
arranged at the KIR locus of chromosome 19 into a centromeric region and a 
telomeric region. Two major haplotypes, A and B, are seen in human 
populations, whereas chimpanzees have only A haplotypes (Pyo et al. 2010). 
The A haplotypes have a fixed gene content, and predominantly encode 
inhibitory KIRs that bind HLA class I as above, whereas B haplotypes are 
characterised by the presence of KIR genes that have little or no binding of 
HLA class I, such as KIR2DS2, KIR2DS3, and KIR2DS5, and may have 
variable numbers of KIR genes (Uhrberg et al. 1997). By reassortment a 
single locus may contain A or B motifs but all haplotypes containing B motifs 
are considered B haplotypes. A dynamic equilibrium maintains both 
haplotypes within human populations, with A haplotypes protecting from 
infection but increasing the risk of disorders of placentation, where NK cells 
play an important role (Khakoo et al. 2004; Nakimuli et al. 2015). Rapid 
evolution at this locus has been demonstrated by the study of isolated human 
populations, including the observation of the emergence of novel KIR genes 
by recombination, particularly where HLA class I variation is limited due to 
founder effects and evolutionary bottlenecks (Gendzekhadze et al. 2009; 
Nemat-Gorgani et al. 2014).  This demonstrates the importance of the 
maintenance of KIR diversity at a population level (Manser et al. 2015).  
During NK cell maturation, NK cells will express inhibitory killer cell 
immunoglobulin-like receptors (KIR) in a seemingly stochastic fashion until 
they express one that interacts with self-MHC, present on almost every cell in 
the body. This process is known as NK cell licencing, and allows for potent 
cytotoxicity when the resultant tonic inhibition is absent (S. Kim et al. 2005; 
Anfossi et al. 2006). Maintenance of KIR expression is dependent on DNA 
methylation, resulting in a variety of NK cell clones in vivo, each with stable 
KIR expression (Chan et al. 2003). Recent work suggests that in individuals 
with certain HLA class I haplotypes, NKG2A-HLA-E interactions can 
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substitute for KIR in NK cell licencing (Horowitz et al. 2016). NK cell licencing 
can be exploited in allogeneic NK cell transfer, where transfer into an HLA-
mismatched recipient removes this functional inhibition (Ruggeri et al. 2002). 
NK cells from patients who do not express HLA class I remain “uneducated” 
and are unable to lyse class I-deficient targets (Zimmer et al. 1998; Furukawa 
et al. 1999). In normal individuals all cytotoxic NK cells express either a KIR 
specific for self-HLA class I, or NKG2A (Valiante et al. 1997). 
The biological consequences of NK cell activation vary depending on the 
setting and the other cells involved in the interaction, and in many settings, 
despite their name, cytotoxicity may be less important than cytokine 
production (Vivier et al. 2008). As effectors, NK cells have important roles in 
tumour surveillance and immunity (see below), and the control of viral 
infection. The evidence for the importance of NK cells in viral infection in 
humans comes from four main sources: clinical observations in NK cell-
deficient humans, observations that certain NK cell receptors or ligands 
confer susceptibility or protection to certain viruses, animal models, and the 
imprint of NK cell-mediated evolutionary pressure on viral infections of 
humans (S.-H. Lee et al. 2007; Jost & Altfeld 2013). Humans with absent or 
defective NK cells are rare, but suffer severe and recurrent herpesvirus 
infections, and also seem to be disproportionately affected by papillomavirus 
and virally-driven malignancy (Biron et al. 1989; Orange 2013) Functional NK 
cell deficiency due to mutation in the FCGR3A gene, which encodes CD16, is 
associated with susceptibility to herpesvirus infections and viral respiratory 
infections (de Vries et al. 1996; Jawahar et al. 1996). KIR genotyping studies 
have shown multiple associations between NK cell receptor repertoire and 
disease outcome, including the protective effect of the activating KIR3DS1 in 
the presence of HLA Bw4-80I in HIV (Bashirova et al. 2011), the protective 
effect of KIR2DL3 in the presence of HLA-C1 in HCV (Khakoo et al. 2004) 
and the recently described protective effect of KIR2DL3 in HBV infection (Di 
Bona et al. 2017). Murine models have demonstrated the importance of NK 
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cells in immune responses to a range of viruses (Biron et al. 1999; Lanier 
2008a). In an early murine cytomegalovirus (MCMV) infection model, NK 
depleted mice had higher viral titres and more severe pathology (Bukowski et 
al. 1983). Subsequent work showed that the activating receptor Ly49H is 
critical for NK cell responses to MCMV (M. G. Brown et al. 2001). More 
recently, Joseph Sun et al demonstrated that following MCMV infection, a 
population of Ly49H+ NK cells expanded rapidly after infection in a DAP12-
dependent manner, and was maintained for several weeks. These NK cells 
expanded following infection demonstrated increased IFNγ production and 
degranulation on stimulation compared with naïve Ly49H+ NK cells, and 
were protective when adoptively transferred into DAP12-/- mice infected with 
MCMV (J. C. Sun et al. 2009). These observations are complimented by 
human data showing complex interactions between human CMV and NK 
cells (Di Bona et al. 2014). CMV can drive NK cell differentiation and 
expansion (Lopez-Vergès et al. 2011; Foley, Cooley, Verneris, Pitt, et al. 
2012), although similar effects have been seen in other viral infections 
(Björkström et al. 2011). For example, NK cells have been shown to be 
important in immune responses to influenza in mice and humans (Gazit et al. 
2006; Draghi et al. 2007). Furthermore, murine models have demonstrated a 
role for NK cells in regulation of immune responses to control immune 
pathology in lymphocytic choriomeningitis virus (Waggoner et al. 2011). In 
this model, NK cell depletion protected against excess immune pathology in 
medium dose infection, but led to high mortality in high dose infection despite 
a reduction in viral load. Reduced survival in high dose infection was CD4 T 
cell-dependent and NK cells were shown to be able to eliminate activated 
CD4 cells to control immune pathology at the expense of viral control. 
Subsequently similar regulatory function was demonstrated in human viral 
infection (Peppa et al. 2013). Additionally, many viral genomes encode 
proteins that help them evade NK cell responses, either by sequestration of 
activating ligands for NK cells or by mimicking inhibitory ligands (Cosman et 
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al. 2001; Wilkinson et al. 2008; Lisnić et al. 2010). Finally, there is evidence 
of KIR “footprints” in the sequences of HIV-1, suggesting adaptation of the 
virus to more strongly bind inhibitory KIR and thereby prevent NK cell 
activation (Alter et al. 2011). However, other authors have suggested that 
many of these polymorphisms cannot be explained by KIR pressure as the 
required KIR-HLA genotype is too scarce within the population (Elemans et 
al. 2017). In any case, several lines of evidence demonstrate the importance 
of NK cells in immune responses to viruses.  
NK cells also have emerging and complex interactions with other arms of the 
immune response. NK cells can delete T cells in chronic viral infection to 
modulate immune pathology (Waggoner et al. 2011; Peppa et al. 2013). They 
can stimulate monocytes to secrete tumour necrosis factor alpha (TNFα) 
(Dalbeth et al. 2004), and in mice are capable of editing the dendritic cell 
(DC) population in a perforin-dependent manner to enhance tumour-specific 
T cell responses (Morandi et al. 2012). In systemic infection NK cells can 
also produce IL-10 in response to IL-12, inhibiting further IL-12 production by 
DCs, acting as a feedback loop to modulate inflammation (Perona-Wright et 
al. 2009). In this way NK cells are thought of as bridging the divide between 
innate and adaptive immunity (Vivier et al. 2011).  
NK cell memory has emerged in recent years as another facet of NK cell 
biology to blur the distinction between innate and adaptive (Cerwenka & 
Lanier 2016). In mice, NK cell memory has been seen in response to 
haptens (O'Leary et al. 2006; Paust et al. 2010) and viruses (J. C. Sun et al. 
2009; Gillard et al. 2011). The hapten-induced contact hypersensitivity (CHS) 
model used by the von Andrian group, based on painting 2,4 dinitro-1-
fluorobenzene or oxalozone onto the ears of mice and measuring ear 
thickness on challenge and re-challenge, may provide the best evidence of 
true NK cell memory behaviour. RAG2 knockout, IL2 receptor γ knockout 
mice (T, B and NK cell deficient) that receive adoptively transferred NK cells 
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from hapten-sensitised mice display much stronger CHS reactions than those 
that receive NK cells from naïve mice, and NK cells transferred 4 months 
after sensitisation induced stronger CHS than NK cells transferred 24 hours 
after sensitisation. This behaviour was replicated on transplant of liver but not 
spleen tissue, and congenically marked NK cells were seen in ear tissue 
following liver transplant and re-challenge with the hapten to which they were 
previously exposed, but not to an alternative hapten. Similar behaviour was 
seen following subcutaneous injection of viral antigens, and liver transplant 
from influenza VLP sensitized mice protected naïve mice from the 
corresponding influenza strain. Anti CXCR6 antibody administered to wild-
type or RAG knockout mice significantly reduced the CHS response on re-
challenge either with haptens or viral antigens, and CXCR6 knockout mice 
did not induce CHS on NK cell adoptive transfer. Finally, sensitised liver NK 
cells were able to specifically kill haptenated B cell targets, but importantly, 
were shown to have equivalent activity to splenic or non-sensitised NK cells 
against MHC knockout targets (Paust et al. 2010). This is the best evidence 
for NK-mediated, long-lived, antigen-specific recall responses, which justify 
use of the term “memory”, although the molecular basis for these responses 
remains uncertain (Paust & Andrian 2011; Rölle et al. 2013). More recently 
NK cells from SHIV infected and SHIV vaccinated rhesus macaques have 
been shown to lyse peptide-pulsed dendritic cells in an antigen specific 
manner using a mechanism dependent of both NKG2C and NKG2A (Reeves 
et al. 2015). Whether the same mechanisms are available to human NK cells 
remains unclear, although their potential applications are already generating 
interest (Cerwenka & Lanier 2016).  
In response to the cytokines IL-12, IL-15 and IL-18, so-called “cytokine-
induced memory NK cells” have been generated, which have high levels of 
perforin and granzyme and on restimulation with IL-2 after adoptive transfer, 
can exert a long-lived anti-tumour effect (Cooper et al. 2009; Ni et al. 2012). 
This combination of cytokines causes demethylation of the conserved non-
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coding sequences upstream of the interferon gamma locus, which may 
explain the increased activity of these cells (Luetke-Eversloh et al. 2014). 
However, other authors have suggested that this is the consequence of the 
poor differentiation of NK cells in mouse houses compared to in free-living 
mice, and that “cytokine-induced memory NK cells” may reflect normal NK 
cell development (Boysen et al. 2011; Riley & Viney 2011). In humans there 
is no evidence for antigen-specific recall responses, but the expanded subset 
of NKG2C+ CD57+ NK cells driven by CMV reactivation in the 
transplantation setting has been labelled “memory-like” (Lopez-Vergès et al. 
2011; Foley, Cooley, Verneris, Curtsinger, et al. 2012). Interestingly, the 
same demethylation pattern at the interferon gamma locus seen in cytokine-
primed NK cells was seen stably imprinted in NKG2C hi NK cells from 
HCMV+ donors (Luetke-Eversloh et al. 2014). More recent work has shown 
that this population is characterised by the epigenetic silencing of the 
transcription factor PLZF, and based on their genome-wide DNA methylation 
pattern, the term “adaptive NK cell” has been used (J. Lee et al. 2015; 
Schlums et al. 2015). 
1.2 NKG2D and its ligands 
NKG2D is one of the C-type lectin-like receptors (Wu 1999; P. Li et al. 2001). 
Unlike NKG2A and NKG2C, which form heterodimers with CD94, NKG2D 
forms a homodimer. In humans, each homodimer recruits two DAP10 
(DNAX-activating protein of 10kD) dimers and signals via their YINM 
domains to give an activatory signal via Vav1 and phosphoinositide 3-kinase 
(PI3K), whereas in mice, NKG2D can signal via DAP10 or DAP12, which 
contains canonical ITAM domains, to signal via Syk and ZAP70 (Lanier 
2015). NKG2D is expressed on NK cells and some T cells (Bauer et al. 
1999). It is highly conserved in humans and other mammals, but the ligands 
are numerous and variable (Eagle & Trowsdale 2007). Regulation of NKG2D 
activity is at the level of the ligands. In humans there are eight known  
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PI3K/Akt pathway Grb2/Vav1/MAPK pathway
Figure 1.3 Human NKG2D and NKG2D ligands.
MICA and MICB are distant homologues of MHC class I and have three domains that
resemble the three domains of the alpha chain of HLA class I, but with no capacity for
peptide binding. ULBP1-6 retain the alpha-1 and -2 domains only, and ULBP1, 2, 3 and 6
are not transmembrane proteins, but are tethered to the cell by GPI anchors.
Akt, Protein kinase B; Grb2, growth factor receptor-bound protein 2; MAPK, mitogen
activated protein kinase; GPI, glycosylphosphatidylinositol; MIC, MHC class I polypeptide-




ligands – MICA, MICB, ULBP1-6, all distant homologues of MHC class I  
(Figure 1.3) (Raulet et al. 2013), that are upregulated in response to cellular 
stresses including DNA damage and viral infection (Gasser et al. 2005; Ward 
et al. 2009). In the mouse, there are five isoforms of retinoic acid early 
inducible-1 (RAE-1α-ε), three isoforms of H60, and the high affinity murine 
UL16-binding protein-like transcript 1 (MULT1). The murine ligands all have 
two extracellular domains, orthologous to the ULBPs, with RAE-1 proteins 
being GPI anchored, whereas H60 and MULT1 are transmembrane proteins 
(Eagle & Trowsdale 2007). 
The biological reason for and purpose of this multitude of ligands is unclear, 
but one reason must be gene duplication to counteract the sequestration of 
NKG2D ligands by specific proteins synthesised by viruses such as CMV 
(Slavuljica et al. 2011). Another product of ligand multiplicity is that it allows 
the expression of NKG2D ligands that engage NKG2D with differing affinities, 
with different functional consequences (Raulet et al. 2013; Spear et al. 2013; 
Zuo et al. 2017). 
NKG2D is known to be important in immune surveillance of cancer and 
tumour immunity (N. Guerra et al. 2008). NKG2D ligands have been found on 
various cancers, often associated with an improved prognosis (McGilvray et 
al. 2009; Cho et al. 2014; Kamimura et al. 2012). Conversely the shedding of 
soluble forms of NKG2D ligands from tumours has been proposed as a 
mechanism of immune escape (Groh et al. 2002; Mincheva-Nilsson & 
Baranov 2014). These ligands are predominantly released by proteolytic 
shedding from the cell surface (Salih et al. 2002; Waldhauer & Steinle 2006), 
although the glycosylphosphatidylinositol (GPI)-anchored ligands can be 
released as part of exosomes (Fernández-Messina et al. 2010). Soluble 
splice variants of some of the NKG2D ligands are known, but their biological 
significance is unclear (Bacon et al. 2004; Gavlovsky et al. 2016). Soluble 
NKG2D ligands are generally thought to act by NKG2D downregulation, 
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impairing the ability of NK cells to respond (Groh et al. 2002; Song et al. 
2006). However, in some murine systems soluble NKG2D ligands act 
differently, blocking a tonic NKG2D downregulation due to ligands expressed 
on the surface of parenchymal cells, resulting in improved NK cell killing 
(Oppenheim et al. 2005; Deng et al. 2015) (Figure 1.4). It is unclear whether 
a similar phenomenon might occur in humans – downmodulation of NKG2D 
function in response to surface-expressed NKG2D ligands has been 
associated with a replacement of DAP10 signalling with DAP12 signalling, a 
transition which is unavailable to human NK cells (Coudert et al. 2005). 
1.3 Other activating receptors 
Other groups of activation receptors also have important roles in NK cell 
function. The natural cytotoxicity receptors NKp30, NKp44 and NKp46 are 
among the best studied, particularly NKp46 and its murine ortholog, NCR1 
(Sivori et al. 1997; Biassoni et al. 1999). NKp46 is expressed by mature NK 
cells and certain ILC subsets (Narni-Mancinelli et al. 2011; Eberl et al. 2015). 
It signals via FCεRI and CD3ζ (Westgaard et al. 2004) and has been 
associated with various ligands including neuraminidase of influenza and 
other viruses, adhesins of Candida glabrata but not other Candida species, 
an unknown ligand of Fusobacterium nucleatum and vimentin, a protein 
synthesised by Mycobacterium tuberculosis-infected cells (Kruse et al. 2014). 
The interactions with viral haemaglutinins are mediated via sialic acid 
residues on NKp46 (Mandelboim et al. 2001). The same group has shown 
that NKp46 may also have a role in tumour immunity, and is involved in killing 
tumour cells, suggesting there may be an undiscovered ligand associated 
with malignancy (Glasner et al. 2012). More recently complement factor P 
(CFP) has been found to be a ligand for NKp46 and the CFP-NKp46 
interaction was shown to be protecting in Neisseria meningitidis infection in a 
mouse model (Narni-Mancinelli et al. 2017). The molecular basis for the 
binding of NKp46 with this diverse range of ligands remains unclear 
Figure 1.4 Competing views of the role of soluble NKG2D ligands in 
cancer
Adapted from Mondelli 2012 and Deng et al 2015. The traditional view has 
been that NK cells recognise surface NKG2D ligands on tumour cells, but 
that soluble NKG2D ligands engage NKG2D, causing its downregulation, 
thereby hiding tumour cells from detection by NK cells (top). Recent 
experiments in a mouse melanoma model (Deng et al 2015) have 
described a system whereby NKG2D is tonically downregulated by 
exposure to NKG2D ligands on resting, healthy cells. The soluble form of 
MULT1, a murine NKG2D ligand, was able to maintain NKG2D expression 
and enhance NK cell killing of melanoma in a dominant fashion. We will 



























(Kruse et al. 2014). Interestingly, overexpression of NKp46 using a flox-cre 
system increased the activity of natural killer cells against influenza and 
tumour metastases in two mouse models (Glasner et al. 2017). 
DNAX accessory molecule-1 (DNAM-1) is a transmembrane glycoprotein of 
the immunoglobulin superfamily. Its main ligands are Nectin-2 and the 
poliovirus receptor (PVR), a nectin-like molecule (Tahara-Hanaoka et al. 
2004). DNAM-1 is expressed on both NK and T cells, and has close 
associations with both the cytoskeleton and the adhesion molecule LFA-1, 
suggesting it may be important in immune synapse formation (de Andrade et 
al. 2014). DNAM-1 appears to cooperate with other activating ligands in the 
killing of target cells, and but NKG2D ligands and DNAM-1 ligands may be 
induced by DNA damage, leaving them well placed to act together in antiviral 
and anti-tumour responses (El-Sherbiny et al. 2007; Carlsten et al. 2007; 
Cerboni et al. 2014). 
1.4 Hepatitis B virus and Chronic Hepatitis B 
The molecular biology of hepatitis B is reviewed in Seeger and Mason 2015 
(Seeger & Mason 2015). In brief, the virion contains a relaxed circular DNA 
genome of 3.2 kb with the DNA polymerase covalently linked (Kaplan et al. 
1973; Summers et al. 1975). Viral tropism is specific for hepatocytes, and 
entry requires the bile acid transporter, sodium taurocholate cotransporting 
peptide (NTCP), as the viral receptor (Yan et al. 2012). On entry into the 
hepatocyte nucleus, synthesis of the positive strand of the DNA genome is 
completed by the viral polymerase to form a covalently closed circular DNA 
genome (cccDNA), establishing a lifelong reservoir of HBV infection 
(Newbold et al. 1995). This structure is long-lived within the nucleus and 
forms the template for mRNA synthesis by host RNA polymerase (Bock et al. 
2001). Seven major proteins are synthesised from the four overlapping open 
reading frames (ORF) (Moolla et al. 2002) (Figure 1.5). Polymerase is a 
reverse transcriptase, RNAse H and primer (Hu & Seeger 2015). Core forms 
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the viral nucleocapsid (Crowther et al. 1994). In the same open reading 
frame preCore is core with a signal peptide at the N-terminus. It undergoes 
post-translational processing before secretion as hepatitis B e antigen 
(HBeAg), the function of which remains uncertain, but may be primarily 
immunomodulatory (M. T. Chen et al. 2004). Three envelope proteins – 
large, medium and small (L, M and S) are produced from the surface open 
reading frame and collectively are called HBsAg – S and M in virions and in 
the various secreted subviral particles, L, which is required for infectivity, 
predominantly in virions (Gripon et al. 1995). The extra domains in M and L 
are called PreS2 and PreS1, respectively. X protein, or HBx is a promiscuous 
transcriptional transactivator that is also required for optimal cccDNA 
transcription (Gearhart & Bouchard 2010). In addition hepatitis B spliced 
protein (HBSP) is synthesised from a spliced pregenomic RNA. Its 
significance is uncertain but it may contribute to fibrosis and to motility of 
hepatoma cells (Soussan et al. 2003; W. N. Chen et al. 2012). An outline of 
the HBV replication cycle is depicted in Zoulim & Locarnini 2009 (Zoulim & 
Locarnini 2009). 
Hepatitis B virus infection can give rise to two diseases, acute hepatitis B 
(less than 6 months from symptom onset to viral clearance) and chronic 
hepatitis B (CHB) (Lavanchy 2004). CHB is primarily the result of infection in 
childhood, with high rates of chronic infection after exposure in childhood and 
up to 90% of infected neonates developing chronic infection (Beasley et al. 
1977; Beasley et al. 1982). By early adulthood more than 95% of infections 
lead to viral clearance, so most epidemiologically important infections occur 
in childhood (Beasley et al. 1983). There are currently 240 million individuals 
chronically infected with hepatitis B, which results in around 750,000 deaths 
annually as a result of cirrhosis or hepatocellular carcinoma (HCC) (Ott et al. 
2012; Stanaway et al. 2016). WHO published a strategy to eliminate viral 
hepatitis in 2016, including targets to treat 80% of eligible individuals with   












































Figure 1.5 Genomic structure of hepatitis B virus.
Adapted from Moolla et. al. 2002. Genome coordinates are given relative to 
the EcoR1 restriction site. The cis-acting regulatory elements are depicted 
as circles and rectangles. The pregenomic and preS2/S transcripts have 
heterogenous start sites, but all transcripts share a common 3’ end due to 
the single polyadenylation signal.
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hepatitis B and reduce viral hepatitis mortality by 65% by 2030 (World Health 
Organization 2016). However, even in rich countries it is uncertain whether 
these goals are achievable (A. Y. Kim 2017). 
The natural history of hepatitis B infection is reviewed in Rehermann 2013 
and Yim and Lok 2006 (Rehermann 2013; Yim & Lok 2006) (Figure 1.6). 
Typically, infected children experience 2-3 decades of high viral load without 
elevation of ALT or the development of liver fibrosis, the so-called “immune 
tolerant” phase. This period is usually clinically silent, although recent work 
shows HBV DNA integration and clonal hepatocyte expansion already occurs 
at this stage, which may be a risk factor for HCC (Mason et al. 2016; 
Marongiu et al. 2008).This is followed by a period of episodes of inflammation 
as some degree of immune control is established, known as the immune 
active phase. Over several years, viral load is reduced and HBeAg 
seroconversion occurs. Infected individuals can then remain in an HBeAg 
negative, low HBV viral load (HBV DNA <2000 IU/ml), low-replicative or 
inactive carrier phase for many years. Progression to liver cirrhosis is 
associated with high viral load, and this inactive carrier phase carries a 
relatively good prognosis (Iloeje et al. 2006). There is a roughly 1% rate of 
HBsAg seroconversion, which is associated with viral control and very good 
prognosis (Y. C. Chen et al. 2002; Arase et al. 2006). A proportion of patients 
develop reactivation of their hepatitis, either with HBeAg positive hepatitis, or 
with HBeAg negative hepatitis as a result of pre-core mutations that reduce 
or abolish HBeAg production (Liaw & Chu 2009). In European patients, 
HBeAg negative CHB, characterised by recurrent, spontaneous flares of 
ALT, is associated with a high risk of progression to cirrhosis and HCC in 
untreated patients (Bonino et al. 1986). These individuals make up a 
significant proportion of the burden of CHB in hepatitis clinics of rich 
countries (Hadziyannis & Vassilopoulos 2001). Hepatitis B vaccine, based on 
HBsAg expressed in a yeast and administered with alum adjuvant, has been 
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Figure 1.6 Phases of chronic hepatitis B infection
Adapted from Yim and Lok 2006. Typically, chronic hepatitis B infection is 
acquired in early childhood, and establishes a steady-state with high viral 
load and low ALT, that may persist for 2-3 decades (HBeAg positive chronic 
infection). At some point a degree of immune control is established over a 
period of several years. During this phase HBV DNA and ALT fluctuate due 
to bouts or flares of hepatitis, and over time the viral load falls and HBeAg, 
a marker of high level viral replication, is replaced by anti-HBe antibodies 
(HBeAg positive chronic hepatitis). Following e antigen seroconversion, a 
state of HBeAg negative chronic infection is established and may persist for 
many years with low viral load and ALT and little liver damage. Some 
individuals may suffer reactivation with HBeAg negative chronic hepatitis. 
Patients may cycle between HBeAg negative chronic infection and chronic 
hepatitis, with each bout of hepatitis resulting in liver damage that is a risk 
factor for HCC and contributes to cirrhosis. 
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know to prevent infection for many years (Whittle et al. 2002). It has been 
successful in reducing HCC in Taiwan and a 30 year follow-up of vaccinees 
in the Gambia is due to report soon (M. H. Chang et al. 1997; Viviani et al. 
2008). However, hepatitis B transmission continues in settings with limited 
resources, largely due to the twin difficulties of the need for a first dose on 
the day of birth in endemic settings, and the risk of transmission from HBeAg 
positive mothers even if vaccine is administered (Wong et al. 1984; Ekra et 
al. 2008; C. Q. Pan et al. 2016). Due to the long timecourse of infection and 
the difficulties in delivering optimal management where it is most needed, 
hepatitis B-associated mortality is rising, and is expected to continue to rise 
into the 2040s (Stanaway et al. 2016; Nayagam et al. 2016). 
There are two main treatment modalities – pegylated interferon alpha and 
nucleos(t)ide analogues. Pegylated interferon alpha is administered as 
injections for a finite duration, has a 20% off-treatment response rate and 
significant side effects (Sonneveld et al. 2010; Rijckborst et al. 2010). 
Nucleos(t)ide analogues are well tolerated but do not clear the virus so must 
be continued indefinitely (Gordon et al. 2013). Viral resistance to these drugs 
is variable, with over 50% resistance to lamivudine after 5 years of therapy, 
whereas no tenofovir resistance has been detected after 7 years of treatment 
(Lok et al. 2003; Buti et al. 2015). Latest guidelines on clinical management, 
published in March 2017, recommend assessment of the virological and 
clinical status of the patient to divide patients into four groups: HBeAg 
positive with chronic infection or chronic hepatitis, HBeAg negative with 
chronic infection or chronic hepatitis (European Association for the Study of 
the Liver 2017). These groups replace the old nomenclature of immune 
tolerant, immune active HBeAg positive, inactive carrier and HBeAg negative 
chronic hepatitis (European Association for the Study of the Liver 2012). In 
low-middle income countries, where 80% of the burden of CHB disease 
occurs, achieving European-level clinical care is often unrealistic (Lozano et 
al. 2012). There have been efforts to devise guidelines more appropriate for 
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this setting, but there is little data upon which to base management (Wiersma 
et al. 2011; World Health Organization 2015). In this and other settings, 
established guidance on nucleos(t)ide discontinuation would be of benefit 
programmatically and to individuals; work is ongoing in this area 
(Papatheodoridis et al. 2016). 
1.5 Hepatocellular carcinoma disease and therapy 
Hepatocellular carcinoma, primary malignancy of the hepatocytes and the 
most common primary liver tumour in humans, is the sixth most common 
human cancer, but the third largest cause of cancer mortality worldwide 
(Lozano et al. 2012). Half is caused by HBV and 30% by HCV, and as a 
result it is common in parts of the world where viral hepatitis is prevalent, 
notably Africa and South/South East Asia (El-Serag 2011). Other major 
causes include alcohol, non-alcoholic steatohepatitis (NASH), 
haemochromatosis and alpha-1 antitrypsin deficiency, and aflatoxin may be a 
cause on its own but is most important as a co-factor in the context of 
another cause. HCC is the most common cause of cancer death in West 
African men (Ferlay et al. 2013).  
HCC is a heterogeneous disease. Transcriptome clustering studies disagree 
about whether HBV-associated HCC forms a distinct group, or whether HBV 
causes HCC in all clusters (Boyault et al. 2007; Hoshida et al. 2009). 
Pathological diversity may have contributed to the failure of a number of 
recent trials of systemic therapy in HCC, and it may be that more 
personalised approaches are required (Llovet & Hernandez-Gea 2014). 
Around 10% of HCC demonstrate highly lymphocytic infiltrates, and these are 
associated with improved prognosis (Kawata et al. 1992; Wada et al. 1998). 
However, data from transgenic mouse models suggests that a cytotoxic T 
cell infiltrate, driven by the expression of HBsAg by hepatocytes, causes 
inflammation leading to HCC (Nakamoto et al. 1998; Guidotti & Chisari 2006). 
This double edged-nature of the lymphocytic response has been highlighted 
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in more recent work from the same group, showing a role for platelets in the 
docking and recruitment of CD8 T cells from the liver sinusoids. By this 
mechanism, antiplatelet therapy reduces inflammation and prevents HCC in 
HBV-transgenic mice (Sitia et al. 2012; Guidotti et al. 2015). Other cell types 
are associated with liver inflammation. In a model of acute hepatitis using 
wild-type splenocytes adoptively transferred into HBV-Env+, RAG-/- mice, 
NKT cells (NK1.1 intermediate, TCR+) downregulated NKG2D, presumably 
following contact with RAE-1 expressing HBV-Env+ hepatocytes. Hepatitis 
could be abrogated by administration of NKG2D blocking antibody, or by 
depletion of NKG2D positive cells (all NK cells and a proportion of NKT cells) 
before adoptive transfer). NKG2D blockade also prevented hepatitis and 
reduced intrahepatic IFNγ and IL4 production after adoptive transfer of 
splenocytes into 1.3 genome HBV transgenic mice (Vilarinho et al. 2007). In 
a model of fibrosis and HCC using mice fed on a choline-deficient, high fat 
diet, a lymphocytic infiltrate of CD4 and CD8 T cells and NKT cells leads to 
steatohepatitis and cancer. RAG-/- knockout and β2 microglobulin knockout 
mice were protected from NASH and HCC, whereas Lymphotoxin β receptor 
2 and LIGHT knockout mice were protected from HCC but not NASH, and 
this effect was associated with a reduction of NKT cells infiltrating the liver, 
suggesting T cells and NKT cells cooperate to induce HCC in a non-
redundant manner in this model (Wolf et al. 2014). An alternative model of 
toxin-induced liver injury comparing fumarylacetoacetate hydrolase (FAH) 
knockout mice with FAH-/-, RAG-/-, IL-2Rγ-/- mice. FAH-/- mice are unable to 
metabolise tyrosine, leading to the accumulation of hepatotoxic metabolites. 
The ensuing hepatitis and fibrosis is lymphocyte-dependent, although these 
lymphocytes (a mixture of NK, NKT and T cells infiltrate the liver in this 
model) also maintain survival. Lymphocytes are not required for liver 
regeneration after hepatitis but are strongly associated with 
hepatocarcinogenesis, with CD8 T cells and Lymphotoxin β having major 
roles (Endig et al. 2016). 
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Various mouse models of HCC have offered instructive insights. Broadly, 
there are three groups of mouse models of HCC, chemically-induced HCC 
models, xenograft models and transgenic models (Heindryckx et al. 2009; He 
et al. 2015). The chemical induction models replicate the cyclical 
inflammation and fibrosis that causes human HCC, so these models tend to 
be favoured. Diethylnitrosamine (DEN) is the most widely used model, it is 
metabolised in vitro via cytochrome P450 to form ethyldiazonium ions, which 
react with nucleophiles including DNA bases. HCC is driven by hepatocyte 
damage, compensatory proliferation, DNA repair and inflammation. A single 
administration causes HCC after 50-100 weeks, with a higher rate in males 
than females (Nakatani et al. 2001). Carbon tetrachloride (CCl4) causes HCC 
in a similar timeframe via Kupffer cell activation and ensuing inflammation 
(Farazi et al. 2006). A choline-deficient diet induces steatosis and 
subsequent HCC, and has been used as a model of NASH-induced HCC in 
humans (E. J. Park et al. 2010). Xenograft models involve injecting HCC cell 
lines either subcutaneously or into the liver in matrigel (orthoptic xenograft). 
Nude mice are used to prevent rejection, which limits these models to drug 
susceptibility proof-of-concept studies (Lu et al. 2007). More recently, tumour 
allograft models have been developed to study immunotherapy, these 
models are more technically demanding but can shed light on the importance 
of tumour immune responses, showing for example a synergistic effect of 
antigen specific CD8 T cells and a tyrosine kinase inhibitor, Sunitinib (Avella 
et al. 2011). There are multiple transgenic mouse models of HCC. 
Constitutive expression of HBx, HBsAg and HCV core all induce HCC after 
12-18 months (Nakamoto et al. 1998; Lakhtakia et al. 2003; Moriya et al. 
1998). Conditional expression of oncogenes such as c-Myc and transforming 
growth factor α under liver-specific promotors can be used to investigate 
carcinogenic pathways, but do not induce the inflammation and fibrosis seen 
in human HCC (Santoni-Rugiu et al. 1996; G.-H. Lee et al. 1992). 
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HBV is unusual in that it can cause HCC in the absence of cirrhosis, using 
various mechanisms (Di Bisceglie 2009). By contrast HCC in the context of 
HCV occurs exclusively in the context of cirrhosis or advanced fibrosis (Lok 
et al. 2011). DNA integration is common in HBV-associated HCC, and 
multiple integrations are associated with poor prognosis (Sung et al. 2012). 
Recent work has demonstrated that DNA integration and hepatocyte 
expansion are more frequent in the early, “silent” phase of infection than 
previously recognised, perhaps explaining why HCC risk remains elevated 
when antivirals are started later in the disease course (Mason et al. 2016). 
Several authors have reported the integration in the promoter region of the 
hTERT gene, encoding the enzyme telomerase, which maintains telomere 
length and is important in stem cells and immortalised malignancy (Gozuacik 
et al. 2001; Ferber et al. 2003). These integrations lead to over-expression of 
telomerase, contributing to immortalisation. HBx protein contributes to 
oncogenesis in a number of ways, including via p53 (S. G. Lee & Rho 2000; 
Knoll et al. 2011), via interactions with SMAD3 signalling (Murata et al. 2008), 
and via reactive oxygen species (S. K. Li et al. 2008). HCC in the context of 
HCV requires a degree of fibrosis/cirrhosis, but also has some direct actions 
via retinoblastoma protein, oxidative stress and PPARα (Korenaga et al. 
2005; Munakata et al. 2007; Tanaka et al. 2008). Inflammation is a significant 
contributor to HCC pathogenesis (J. Huang et al. 2014; Grivennikov et al. 
2010) (Figure 1.7). Viral infection in the liver activates Kupffer cells to 
produce IL-6 and hepatocyte growth factor, which directly drive hepatocyte 
proliferation and induce liver cancer in mice (Maeda et al. 2005), and also IL-
10, TGFβ and TNFα (Budhu & X. W. Wang 2006). IL-6 in particular is a 
crucial mediator of HCC and differences in its expression may account for the 
difference in HCC rates between males and females (Naugler et al. 2007). 
TNFα induces apoptosis in neighbouring hepatocytes in mice deficient in the 
tumour suppressor CYLD, which may increase DAMP signalling and 
encouraging compensatory proliferation (Nikolaou et al. 2012). Both IL-6 and 
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TNFα are also implicated in obesity-associated HCC in a choline-deficient 
diet model (E. J. Park et al. 2010). Lymphotoxin α and β are upregulated in 
HBV, HCV and HCC and their over-expression causes HCC in transgenic 
mice by inducing chemokines CCL2, CXCL10, CXCL1 and CCL7, which in 
turn recruit circulating inflammatory cells (Haybaeck et al. 2009). TGFβ 
promotes proliferation in HBV-infected cells and contributes to 
retrodifferentiation and epithelial-mesenchymal transition along with IL-6 
(Dubois-Pot-Schneider et al. 2014). Not only are multiple pro-inflammatory 
and carcinogenic pathways activated, but there is also induction of 
immunosuppressive mechanisms to downregulate anti-tumour surveillance. 
For example, IL-10 impairs T and NK cell function (Das et al. 2012; Peppa et 
al. 2010). Recent transcriptomic data has suggested that tumour-infiltrating 
macrophages in HCC express high levels of IL-10, which may impair the 
function of NK cells recruited via CXCL10/CXCR3 (Chew et al. 2017). 
In rich countries, early stage HCC is curable, but most cases present too late 
for curative resection. The disease is intrinsically resistant to standard 
chemotherapy and radiotherapy, as a result average 5-year survival in the 
USA is less than 15% (El-Serag 2011). Sorafenib, a tyrosine kinase inhibitor, 
is the only licenced treatment, it improves survival by around three months 
(Llovet et al. 2008). The prognosis in hepatitis B-associated HCC can be 
improved by treatment with nucleos(t)ide analogues after tumour resection, 
although this becomes apparent only after 2 years, so is probably due to 
control of viral replication and resultant inflammation preventing new primary 
HCC, rather than by a direct effect (G. Huang et al. 2015). Local therapies 
such as trans-arterial chemo-embolisation (TACE) or radio-frequency 
ablation are often used to reduce disease burden, but are not curative (Bruix 
et al. 2004). As a result of this dire situation, there has been much excitement 
about the prospect of immunotherapies for HCC (Prieto et al. 2015). 
Nivolumab, a programmed death 1 (PD-1) blocking antibody was recently 
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Figure 1.7 Cartoon of mechanisms of HCC carcinogenesis in chronic viral hepatitis
HBV is capable of carcinogenic insults via DNA integration as well as through viral replication 
and ensuing inflammation. HCV is an RNA virus, so does not interact directly with host DNA, 
although some HCV proteins have oncogenic function. However the major route of carcino-




shown to have a 20% response rate in HCC in a phase 1-2 trial, phase 3 
trials are underway (El-Khoueiry et al. 2017).  
There has been some interest in the expression of NKG2D ligands and their 
potential as immunotherapeutic agents/targets in HCC (Mondelli 2012). In a 
Japanese cohort, HCC was shown to express MICA and ULBP1, but only 
ULBP1 was associated with good prognosis (Kamimura et al. 2012). Soluble 
MICA has been seen in HCC patients from China and Japan, and is 
associated with impaired peripheral NK cell function and poor prognosis 
(Jinushi et al. 2003; Kumar et al. 2012; Fang et al. 2014; J.-J. Li et al. 2013). 
However there are no data on soluble NKG2D ligands in African HCC 
patients or on the ULBPs. These studies suggest that NKG2D-mediated 
control of HCC is beneficial. However, experiments with diethylnitrosamine 
(DEN)-induced HCC in NKG2D knockout mice suggest that NKG2D may 
drive carcinogenesis by exacerbating inflammation and increasing 
hepatocyte turnover and compensatory proliferation (Sheppard et al. 2017). 
Another contradictory finding is that the SNP at rs2596542, associated with 
MICA shedding in HCC, has differential effects depending on the cause of 
HCC, with A/A genotype at high risk of HCC in HCV infection, whereas in 
HBV infection the G/G genotype carries a high risk of HCC (Kumar et al. 
2011; Kumar et al. 2012; Tong et al. 2013). Another observation suggesting 
NKG2D function may be deleterious in HCC is that the high-affinity MICA-
129Met allele is associated with increased risk of HCC in the context of HBV 
(Tong et al. 2013). 
1.6 NK cells in the liver and liver diseases 
One of the major functions of the liver is as a capillary bed between the gut 
and the rest of the body, to remove toxic and bacterial products from the 
portal circulation before they can circulate (Crispe 2009). During normal liver 
function this must be achieved without inflammation, despite the constant 
exposure to both foreign antigens and danger signals. As a result, the liver is 
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a tolerogenic organ, able to be transplanted across HLA haplotypes without 
requirement for long-term immunosuppression and to protect other co-
transplanted organs from rejection (Calne et al. 1969; Rosen 2008). 
Tolerance is maintained by multiple mechanisms, an important one being 
hepatic priming leading to T cell deletion (Bowen et al. 2004; Holz et al. 
2012). Several infections have evolved to specifically infect the liver and 
exploit this tolerogenic tendency (Protzer et al. 2012). NK cells, by 
responding to altered self rather than foreign antigen, can go some way in 
making up for impaired hepatic T cell immunity without responding to 
ingested foreign antigen (Rehermann 2015). The fenestra in specialised liver 
sinusoidal endothelial cells allow intravascular lymphocytes to make direct 
contact with parenchymal cells to mediate cellular immunity (Guidotti et al. 
2015). 
NK cells are found in many tissues throughout the body (Björkström et al. 
2016). In the liver NK cells comprise 30-50% of the intrahepatic lymphocyte 
pool (Doherty et al. 1999). They correspond to the pit cells seen in electron 
micrographs of inflamed liver (Kaneda et al. 1984). They are known to have 
complex regulatory interactions with Kupffer cells, the resident macrophages 
of the liver (Tu et al. 2008). 
Recent work by our group and others has identified a liver-resident NK cell 
population characterised by an Eomes-high, Tbet-low transcriptional profile, 
and by the expression of CD69 and CXCR6 (Stegmann et al. 2016; Harmon 
et al. 2016; Hudspeth et al. 2016; Lugthart et al. 2016) (Figure 1.8). These 
cells make up 20-80% of the intrahepatic NK cell population, are a subset of 
the CD56bright NK cells previously described in the liver, but are distinct from 
the CD56bright peripheral NK cells. These cells may be long-lived, and IL-15 
and TGFβ may be the drivers of the Eomes-high transcriptional profile (Cuff 
et al. 2016). Liver resident NK cells make similar amounts of IFNγ and have a 
similar degranulation potential (measured by CD107a expression on 
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stimulation) to their non-resident but intrahepatic counterparts, however they 
contain lower levels of granzyme B and perforin ex vivo (Stegmann et al. 
2016). In addition there is a smaller population (0-12% of the intrahepatic NK 
cell pool) of CD49a+ NK cells, which are CD56bright but express NKG2C 
and KIR and have been suggested to be analogous to the CD49a+, DX5- 
memory NK cells in the mouse (Marquardt et al. 2015; Paust et al. 2010; 
Peng et al. 2013). They do not express CD57, and contain high levels of 
granzyme B but low levels of perforin. These cells are Tbet-high, Eomes-low 
and do not overlap with the CXCR6+ CD69+ liver resident pool. 
NK cells are implicated in a variety of liver diseases (Male et al. 2017). Liver 
fibrosis, driven by activated stellate cells, is a common pathway in 
inflammatory diseases of the liver. Increased NK cell infiltrate in primary 
sclerosing cholangitis is associated with reduction in fibrosis, and NK cells 
have been shown to kill activated hepatic stellate cells in culture via a variety 
of mechanisms (Berglin et al. 2014; Glassner et al. 2012). In vivo, NKp46 has 
been implicated in killing of hepatic stellate cells and attenuation of liver 
fibrosis (Gur et al. 2012).  
The bulk of NK cell research in human liver disease has focused on viral 
hepatitis, specifically hepatitis B and C. Immune responses to HBV are 
reviewed in Bertoletti and Ferrari 2012 and Protzer 2012 (Bertoletti & Ferrari 
2012; Protzer et al. 2012). CD8 T cells are crucial for viral clearance, in 
chronic disease T cells are exhausted due to impaired priming and the 
tolerogenic nature of the liver (Thimme et al. 2003). It is important to observe 
that the nomenclature for CHB disease stages is a clinical, not 
immunological, description. CD8 T cell responses are most easily detectable 
in patients with “inactive” CHB, and HBV specific T cells are found in 
“immune tolerant” individuals at similar levels to “immune active” individuals 
(Maini et al. 2000; Mason et al. 2016). However, there is significant deletion 





























Figure 1.8 Comparison of peripheral blood and intrahepatic NK cell populations. 
(A) Peripheral blood NK cells form two populations, the majority CD56dim and a small
population of CD56bright NK cells. In the liver there are similar sized populations of CD56
bright and dim NK cells. Following the publication in 2016 of a number of articles it has been
shown that the intrahepatic CD56 bright population is comprised primarily of CXCR6+
CD69+, liver resident NK cells with a distinct transcriptional profile.
(B) CXCR6- CD69- intrahepatic NK cells are phenotypically similar to their peripheral blood
counterparts. CXCR6+ CD69+ NK cells are phenotypically distinct. They do not express












(Webster et al. 2004), mediated at least in part by CTLA-4 and BIM (BCL2-
interacting mediator of cell death) (Schurich et al. 2011; Lopes et al. 2008). 
The remaining HBV-specific CD8 T cells are markedly dysfunctional, 
expressing high levels of the negative regulators PD-1 and Tim-3, inhibiting 
the production of the important antiviral cytokine IFNγ (Boni et al. 2007; 
Nebbia et al. 2012). T cell function is further inhibited by metabolic 
dysfunction induced by myeloid-derived suppressor cells (Pallett et al. 2015). 
In the relative absence of HBV-specific T cells, non-specific T cells make a 
significant contribution to liver pathology (Maini et al. 2000; Rehermann 
2013), facilitated by neutrophil-derived matrix metallo-proteinases (Sitia et al. 
2004). 
In NK cells in chronic hepatitis B, there is impairment of cytokine function with 
preserved cytotoxicity, due to the induction of IL-10 production by HBV 
(Oliviero et al. 2009; Peppa et al. 2010). NK cells tend to be reduced in 
number but with a more activated phenotype in the immune active phase 
compared with in the immune tolerant phase (Sprengers et al. 2006; Tjwa et 
al. 2011). NK cells can kill infected hepatocytes via TRAIL, but also kill 
antiviral CD8 T cells via TRAIL, so their overall contribution to pathology may 
be mixed (Dunn et al. 2007; Peppa et al. 2013; Maini & Peppa 2013) (Figure 
1.9). In addition, activated and HBV-specific CD4 T cells in the infected liver 
upregulate MICA and can be killed by NK cells via NKG2D (W.-C. Huang et 
al. 2017). Treatment with nucleos(t)ide analogues control viraemia and 
reduce NK cell activation, with an associated restoration of HBV-specific CD4 
T cells (Boni et al. 2015). In contrast, treatment with pegylated IFNα leads to 
an increase in circulating IL-15, associated with an expansion of activated 
CD56bright NK cells (Micco et al. 2013; Gill et al. 2016). 
In hepatitis C, NK cell cytotoxicity is associated with protection in high-risk 
individuals, and with better treatment outcomes following pegylated interferon 
therapy (Khakoo et al. 2004; Golden-Mason et al. 2010; Ahlenstiel et al. 
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2011; Oliviero et al. 2013). Similar to CHB, IFNγ production is impaired in 
chronic HCV (Edlich et al. 2011). NKp46 appears to be an important 
activating receptor associated with control of HCV (Krämer et al. 2012). 
In a small series of HCC patients, tumour-infiltrating NK cells had reduced 
perforin and granzyme B compared with liver NK cells (Cai et al. 2008). This 
is in keeping with NK cells infiltrating other solid tumours, which are 
functionally impaired by multiple mechanisms including regulatory T cells, 
myeloid derived suppressor cells and immunosuppressive cytokines 
(Guillerey et al. 2016). NK cells are likely to have a role in HCC in the context 
of HBV, as KIR-HLA interactions predictive of strong NK cell function 
contribute to early age of onset of HCC (N. Pan et al. 2013). Interestingly, IL-
2 stimulated liver-derived NK cells were better than IL-2 stimulated peripheral 
NK cells at killing HepG2 cells in vitro (Ishiyama et al. 2006). 
Metastases to the liver are common in a wide range of malignancies, 
including lung, breast and GI cancers. Colorectal metastases can be studied 
as they are commonly resected with curative intent (Chua et al. 2012). In a 
recent study, NK cell infiltration was associated with good prognosis, and has 
previously been associated with response to chemotherapy (Donadon et al. 
2017). This is in contrast to primary colorectal tumours, where few NK cells 
are found (Halama et al. 2011). Whereas in HCC inflammation may drive 
carcinogenesis, in colorectal metastases to the liver activation of NLRP3 
inflammasome induces IL-18, which drives NK cell mediated anti-tumour 
responses in mice (Dupaul-Chicoine et al. 2015). In primary colorectal 
tumours, MICA expression is associated with good prognosis following 
resection (Watson et al. 2006; McGilvray et al. 2009). This may not be due to 
an effect in the gut, where NK cells are few and secondary metastases are 
rare, but may be a consequence of NK cell-mediated clearance of MICA-


















Figure 1.9 NK cell interactions in the liver sinusoid
NK cells have been shown to kill T cells, stellate cells and hepatocytes in 
various settings including HBV infection. They have regulatory interactions 
with Kupffer cells and may take advantage of the slow blood flow through 
the hepatic sinusoid to have interactions with other cell types such as liver 
sinusoidal endothelial cells (LSEC) or regulatory T cells (T reg). Figure 
kindly provided by Anna Schurich, Maini group
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1.7 NK cell immunotherapy 
NK cells are specialised anti-cancer cells, and oncologists have tried to use 
NK cells to treat human cancers in different ways for many years (Rosenberg 
et al. 1985), with most success in haematological malignancy. 
Various groups have tried to use KIR-ligand mismatched haematopoietic 
stem cell transfer, and although early results were conflicting (Davies et al. 
2002; Ruggeri et al. 2007), with improved patient selection and concentrating 
on the most promising clinical scenarios there may be a role for KIR-ligand 
mismatch in acute myeloid leukaemia (Heidenreich & Kroger 2017) and 
clinical trials are ongoing (NCT02646839). Activating KIR may also have an 
important role to play (Mancusi et al. 2015; Stringaris et al. 2010). 
In solid tumours, progress on NK cell immunotherapy for cancer has been 
slower (Morvan & Lanier 2016). One of the problems is the state of anergy 
induced in NK cells by the tumour environment (Ardolino et al. 2014). 
Checkpoint blockade targeting T cells has been a significant advance in 
cancer immunotherapy (Couzin-Frankel 2013). It may be that similar 
approaches could be used in NK cells, however PD-1 expression by NK cells 
is absent in most people, and where present seems to be driven by CMV 
rather than tumour (Pesce et al. 2017; Chiesa et al. 2016). However NK cells 
can express LAG3 and Tim3, and KIR blockade might be analogous to 
checkpoint inhibition for NK cells - anti-KIR antibodies are safe in humans 
(Vey et al. 2012). 
NKG2D ligands make attractive targets for cancer immunotherapy, as they 
are upregulated by a wide variety of tumours (Spear et al. 2013). One logical 
approach is to use the binding domain in NKG2D but with one or more 
signalling domains to give strong activating signals, an NKG2D chimeric 
antigen receptor (NKG2D-CAR) and transfect this receptor into a cytotoxic T 
or NK cell for adoptive transfer (Sentman & Meehan 2014). Transfection of 
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NK cells with a NKG2D-DAP10-CD3ζ CAR improved NK cell cytotoxicity and 
control of a mouse model of osteosarcoma (Y.-H. Chang et al. 2013). 
ADCC is another important mechanism by which NK cells can control 
tumours (W. Wang et al. 2015). Rituximab was the first tumour antibody 
shown to act via ADCC in control of B cell lymphomas (Cartron et al. 2002; 
Dall'Ozzo et al. 2004). In solid tumours, Trastuzumab and Cetuximab, for 
HER2+ breast cancer and EGFR+ colorectal cancer respectively, also 
achieve at least some of their activity via ADCC. As techniques in molecular 
biology progress, novel bispecific proteins combining antibody variable 
regions, often smaller than full Fab fragments, and NKG2D ligands, are being 
developed to recruit NK cell activity against tumours such as colorectal 
cancer and HCC (Rothe et al. 2013; T. Wang et al. 2016). 
The use of cytokines as therapeutic agents for cancer has been limited by 
their toxicity (Floros & Tarhini 2015). However IL-15 has been shown in a 
number of settings to enhance the anti-tumour properties of NK cells 
(Sutherland 2006; Mao et al. 2016). As a result researchers have sought 
ways to utilise the IL-15 effect while avoiding the toxicity associated with 
systemic administration. IL-15 signalling drives persistence in IL-15-CAR T 
cells (Hurton et al. 2016), and a similar approach has been tested in NK 
cells. An NK cell line transfected with IL-15 signals in an autocrine fashion to 
control HCC in mouse models (Jiang et al. 2014). The group of Dario 
Campana has used transfection with a membrane bound IL-15 (mbIL-15) 
constructs in different ways to augment NK cell anti-cancer function. K562 
cells transfected with mbIL-15 and 4-1BB ligand can expand and activate NK 
cells for use in HCC immunotherapy (Kamiya et al. 2016). Retroviral 
transduction of human NK cells with mbIL-15 enhanced persistence, 
cytotoxicity and tumour control in a model of human AML in NOD/scid/IL2R 
gamma null mice (Imamura et al. 2014). An IL-15 superagonist ALT-803, that 
combines IL-15, IL-15Rα and an Fc domain that improves the half life without 
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recruiting complement or ADCC, has been investigated as an anti-cancer 
agent, but in humans may have similar toxicity to IL-15 alone (Rosario et al. 
2016). One way to reduce toxicity might be to target IL-15 to the tumour 
environment, as has been demonstrated in vitro with an ALT-803-rituximab 
fusion protein (B. Liu et al. 2016). 
1.8 Aims of this thesis 
1. To comprehensively investigate the NKG2D receptor-ligand system in the 
setting of hepatocellular carcinoma by assessing soluble NKG2D ligands and 
their effect on NKG2D expression and function in circulating and tumour-
infiltrating NK cells. 
2. To construct a model of the interaction between tumour-infiltrating NK cells 
and HCC to be used to interrogate the functional consequences of  
NKG2D/NKG2D ligand interactions in this setting. 
1.9 Knowledge Gaps 
The release of soluble NKG2D ligands other than MICA/MICB by HCC and 
many other solid tumours is not known. 
Although the expression of soluble and cell surface NKG2D ligands by HCC 
has been associated with poor and improved prognosis respectively, this 
data is purely observational. No investigations of the effect of NKG2D 
expression on NK function in this setting exist. 
There is uncertainty about the functional consequences of the presence of 
soluble NKG2D ligands on NK cells in humans, particularly whether soluble 
NKG2D ligands can protect against NKG2D downregulation and enhance 
cytotoxicity. 
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NK cells are known to infiltrate HCC, but it is not known whether these NK 
cells infiltrate from the surrounding liver tissue or the bloodstream, what 
mechanisms inhibit their function or whether function might be restored by 
targeting the NKG2D pathway. 
The contribution of NK cells to the infiltrating lymphocyte pool in metastases 
from non-HCC primary tumours eg colonic adenocarcinoma to the liver is 
unknown. 
NK cells are known to lyse tumour cells, but NK cells infiltrating solid tumours 
lose activity via unknown an mechanism(s). A model of NK cells infiltrating a 
solid tumour could be used to investigate agents to impair or reverse this 
mechanism. 
1.10 Hypothesis 
NK cells, via NKG2D-mediated interactions, can successfully control HCC 
through cytotoxicity or other effector functions, but HCC is able to evade this 
control by manipulation of NKG2D ligands, thereby manipulating NKG2D 
function in NK cells, and that it is possible to intervene to restore NKG2D 
function in tumour-infiltrating NK cells. 
1.11 Research Questions 
1. Which soluble NKG2D ligands are released by hepatitis B-associated 
HCC? 
2. Does soluble ligand release affect NKG2D expression by circulating NK 
cells and if so, does this impact effector function? 
3. Does NKG2D ligand expression have prognostic association and are these 
independent of disease staging and other known prognostic markers? 
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4. Is NKG2D ligand expression related to the aetiology of the HCC? 
5. Is soluble NKG2D ligand expression seen in secondary liver tumours? 
6. What is the mechanism by which NKG2D ligands are induced? 
7. Do NK cells infiltrating HCC resemble circulating or intrahepatic NK cells? 
8. Do tumour-infiltrating NK cells have altered NKG2D expression? 
9. Do tumour-infiltrating NK cells have altered effector function? 
10. Does exposure to HCC in vitro alter NK cell NKG2D expression or 
effector function? 
11. Can NK cell effector function be protected from the effect of HCC by 
targeting the NKG2D pathway? 
12. Can other pathways be used to maintain NK cell effector function in the 
context of HCC? 
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Chapter 2 Materials and Methods 
2.1 NKG2D Ligand ELISA 
ELISAs for MICA, MICB, ULBP1, ULBP2 and ULBP3 (R&D) were performed 
as per the manufacturer’s instructions. Briefly, 96 well flat bottom plates 
(Falcon) were coated overnight at room temperature with capture antibody 
diluted in phosphate buffered saline (PBS) (Sigma). Plates were washed 
three times by mechanical plate washer in wash buffer comprised of PBS 
with 0.05% Tween-20 (Fisher), and blocked for one hour in a reagent diluent 
of PBS with 1% fraction V BSA (Fisher). Thawed patient serum was diluted 
one part in three with reagent diluent and standards and a blank were 
prepared by serial dilution in the same reagent diluent. All samples and 
standards were assayed in duplicate. Samples were incubated for two hours 
at room temperature and the plates were washed three times. Detection 
antibody diluted in reagent diluent was added at the recommended 
concentration and incubated for a further two hours before washing three 
times. Streptavidin HRP at 1:200 in reagent diluent was added for 20 minutes 
and a final three washes performed. The plates were developed using 
Substrate Reagents A+B (R&D) for 20 minutes in the dark and the reaction 
stopped with Stop Solution (2N HCl) (R&D). Plates were read immediately 
using an automated plate reader (Finstruments Multiskan) at 450nm. Mean 
optical densities (OD) for each standard and sample were taken and antigen 
concentrations were calculated using Excel for Mac 2011 (Microsoft) to 
calculate a trend line of the format y=axb in order to interpolate a 
concentration from the Mean OD. Statistical tests were performed using 
Graphpad Prism 6. 
2.2 Exosome isolation 
Exosomes were isolated from serum using Izon Science qEV Size Exclusion 
Columns according to the manufacturer’s instructions. 
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2.3 Tumour-conditioned media 
Small fragments of tumour (less than 0.1g) were weighed. Their mass in mg 
was multiplied by 10 and this many microlitres of CRPMI+10% FBS was 
added. The tissue was incubated overnight at 37°C. The supernatant was 
removed and centrifuged in a microcentrifuge at 2000 rpm for 5 minutes to 
pellet any cells or debris. The supernatant was removed for use in ELISA. 
2.4 Imagestream 
For identification of exosomes in serum, Fc receptor blocking reagent 
(Miltenyi) was added to paired serum, exosome and protein fractions before 
staining with BODIPY-FL (ThermoFisher), CD45 PE-Cy7 (eBioscience) and 
ULBP1-PE (R&D). Samples were fixed with Cytofix (BD) before acquisition. 
For NKG2D internalisation assays NK cells were surface stained with CD56 
PE-Cy7 (Beckman Coulter), CD3 PE Texas Red (BD) and 1:10,000 DAPI 
(ThermoFisher) and fixed in cytofix/cytoperm before intracellular staining with 
NKG2D Alexa 488 (R&D). Samples were acquired by ImagestreamXL 
(Amnis) and data analysis performed using IDEAS software (Amnis). 
2.5 PBMC isolation and storage 
PBMC were isolated by density gradient centrifugation using Ficoll-Hypaque 
(GE Healthcare). Peripheral blood was collected into vacutainers containing 
EDTA (BD) or lithium heparin (BD). Using 15ml falcon tubes (Sarstedt), 10ml 
blood was carefully layered onto 5ml Ficoll-Hypaque and centrifuged at 2000 
rpm, acceleration 6, brake 4 in a Thermo Multifuge centrifuge. The PBMC 
layer was removed using a Pasteur pipette and washed in Roswell Park 
Memorial Institute (RPMI) medium (Gibco). Cells were either stained 
immediately for flow cytometry or counted using trypan blue (Sigma) and 
transferred to freezing medium (FBS (Sigma) with 10% dimethylsulfoxide 
(DMSO) (Sigma) at a concentration of 10 million cells/ml for 
cryopreservation, initially at -80°C before transfer to liquid nitrogen for long-
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term storage. Before use cells were thawed in a water bath at 37°C and 
washed in 20ml RPMI. 
2.6 Intrahepatic lymphocyte isolation from biopsies 
Liver biopsies were separated into single cell suspension by mechanical 
dissociation by hand. A cell scraper (Sarstedt) was used to gently disperse 
the liver cells into RPMI. Clumps of cells were removed by filtration with 
70µm filter (Greiner), cells were washed in RPMI and used immediately. 
2.7 Intrahepatic lymphocyte isolation from tissue explants 
Single cell suspensions from surgical resection of liver and tumour tissues 
were generated by enzymatic digestion and mechanical dissociation as 
described in(Stegmann et al. 2016). In brief, tissues were cut into small 
pieces and incubated for 30 minutes at 37°C in HBSS buffer containing 
0.0001% Danas (Roche) and 0.01% collagenase (ThermoFisher). Samples 
were transferred to C-tubes (Miltenyi Biotec) and processed by gentleMACS 
(Miltenyi Biotec) using the liver program. Tissue and supernatants were 
filtered by 70µm filter and centrifuged at 500rpm to knock down large 
hepatocyte clumps. The supernatant was centrifuged and the pellet 
resuspended in 30% percoll (GE Healthcare) before further centrifugation at 
2000rpm for 10 minutes. The pellet was resuspended in HBSS and layered 
onto Ficoll-Hypaque as for peripheral blood separation. The lymphocyte layer 
was removed and cells counted by ADAM counter (NanoEntek) and used 
immediately. 
2.8 Intrahepatic lymphocyte isolation from liver perfusates 
Organ transport and perfusion fluid from liver transplantation may contain 
large numbers of intrahepatic lymphocytes. Perfusion fluid is centrifuged in 
50ml falcon tubes (Sarstedt) at 1800 rpm for 15 minutes and the supernatant 
discarded. The tubes are then vortexed to disrupt the pellet and the cells 
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pooled and resuspended in RPMI before density gradient centrifugation over 
Ficoll Hypaque as above. 
2.9 Flow cytometric staining 
All samples were treated with Fc receptor blocking reagent (Miltenyi Biotec) 
before staining. Surface staining was performed in 96 well plates (Sarstedt) 
in staining buffer of 50% PBS, 50% Brilliant Violet staining buffer (BD). 
Fixable live/dead stain (Life Technologies) was added to the staining buffer. 
Antibody staining was conducted for 15 minutes at 37°C in the dark before 
washing with PBS. Samples for surface staining only were fixed in Cytofix 
(BD). Samples for intracellular staining were fixed in cytofix/cytoperm (BD) for 
20 minutes at 4°C in the dark before staining with intracellular antibodies in 
saponin buffer (PBS + 1% FBS (Sigma) + 0.1% saponin (Sigma)) for 30 
minutes at 4°C in the dark. Samples were then washed once in saponin 
buffer and once in PBS. 
Intranuclear staining was performed using FoxP3 staining buffer (BD). 
Surface staining was as above, then cells were fixed in buffer A for 10 mins 
at room temperature followed by buffer A with 1:50 buffer B for 30 mins at 
room temperature. Samples were washed in PBS and intranuclear staining 
performed in PBS for 30 mins at 4°C in the dark. 
For staining for phospho-ERK, stimulated cells were immediately cooled on 
ice to minimise alterations in pERK, then conjugated antibodies for surface 
markers were applied on ice for 30 mins. Cells were washed in PBS, then 
fixed in Cytofix for 10 mins at 37°C. Permeablisation in Perm III buffer (BD) 
for 25 mins at -20°C was followed by staining with anti-pERK (Cell Signalling 
Technologies) for 30 mins at 4°C. 
Single fluorochrome compensation controls were made using compensation 
beads (BD). Compensation matrices were calculated initially in FACSDiva 
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and edited where necessary in FlowJo X (TreeStar). Samples were acquired 
on LSR Fortessa or Fortessa X20 (BD) and data analysed in FlowJo X. 
2.10 Image Analysis and Quantitation of NKG2D internalisation 
Magnetic bead isolated NK cells were cocultured with PLC/PRF/5 cells as 
described below. Cells were surface stained with anti CD3 PE-CF594, anti 
CD56 PE-Cy7, permeablised and stained intracellularly with anti NKG2D 
APC and then DAPI nuclear stain. Events were acquired on the 
ImagestreamX (Amnis) and data transferred to IDEAS software (Amnis) for 
analysis. Single cell events were identified by gating on Brightfield Area vs 
Brightfield Aspect Ratio. A histogram of Brightfield Gradient Root Mean 
Square was used to identify events in focus. CD56 positive, CD3 negative 
events within this population were gated on. Using the built-in “Internalization 
Wizard” an object mask was drawn around the cells using the brightfield 
image, and eroded 4 pixels. For each cell a ratio of the logarithm of the 
intensity of the internal brightness to the total brightness was generated, 
using the APC channel. The ratio was scaled by the wizard such that cells 
with half the signal intensity internally (50:50 surface:internal brightness) had 
an internalisation value of 0, and cells with positive values had predominantly 
internal NKG2D staining. 
2.11 Media 
Lymphocyte short-term cultures were in complete RPMI + 10% FBS. To 
500ml RPMI was added: 10ml 1M Hepes, 10ml 50x MEM essential amino 
acids, 5ml 100x MEM non-essential amino acids, 0.5ml 50mM 2-
mercaptoethanol, 2.5ml 100mM sodium pyruvate, 5ml penicillin/streptomycin 
10,000IU/ml (all Gibco), 50ml FBS. 
PLC/PRF/5 cells, HepG2 cells and K562 cells were grown in complete RPMI 
+8% FBS, prepared as above but with 40ml FBS and 5ml amphotericin B 
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250µg/ml (Sigma). Cell lines were cultured in 75cm2 or 175cm2 flasks (Nunc) 
and split using trypsin-EDTA (Gibco). 
HepG2.117, HepG2 AD38 and HepG2 NTCP cells were grown in a 
containment level 3 laboratory in Dulbecco’s modified Eagle medium (DMEM) 
(Gibco) + 10% FBS + 5ml penicillin/streptomycin. 
2.12 NK cell isolation 
Untouched NK cells were isolated from PBMC or intrahepatic lymphocytes 
using magnetic beads by negative selection, according to the manufacturer’s 
instructions (Miltenyi Biotec), achieving >95% purity and viability. 
2.13 NK cell – PLC/PRF/5 cocultures 
PLC/PRF/5 cells were plated at a density of 50,000 cells/well in 48 well 
plates (Costar) and incubated in 0.5ml CRPMI+8% FBS for three days to 
adhere to the bottom of the well and grow to semi-confluence. Media was 
changed and isolated NK cells were added at 200,000 per well, centrifuged 
at 300 rpm for 3 minutes and incubated at 37°C for 12 hours. Reagents 
added the appropriate conditions were: recombinant human NKG2D final 
concentration 1µg/ml (Sino Biological), anti-MICA (R&D), recombinant human 
MICA final concentration 1µg/ml (Sino Biological), recombinant human 
ULBP1 final concentration 1µg/ml (Sino Biological), anti-DNAM1 final 
concentration 4µg/ml (R&D), anti-TGFβ receptor final concentration 2µg/ml 
(R&D), anti-IL6 receptor final concentration 4µg/ml (R&D), anti-HLA ABC 
(BioLegend), recombinant human IL-15 final concentration 1ng/ml (R&D). 
0.4µm transwell inserts (Falcon) and 3-day PLC/PRF/5 media mixed 1:1 with 
fresh CRPMI+10% FBS were used for contact experiments. Supernatants 
containing NK cells were removed and washed with PBS containing EDTA 
(Sigma) and FBS. For some experiments, removed NK cells were 
resuspended in fresh medium and incubated for 18 hours in the presence of 
 66 
IL-2 20IU/ml (Miltenyi biotec), IL-12 12.5pg/ml (R&D), IL-18 5ng/ml (MBL), IL-
15 1ng/ml (R&D), IFNα 10U/ml (PBL Interferon) or medium alone. 
2.14 Primary Human Hepatocyte culture and HBV infection 
These experiments were performed by Dr Ana Maria Ortega Prieto and 
colleagues in the laboratory of Dr Marcus Dorner at Imperial College London. 
Their methodology has recently been accepted for publication as: Ortega-
Prieto AM, Skelton JK, Wai SN, et al (2018). 3D microfluidic liver cultures as 
physiological preclinical tool for hepatitis B virus infection, Nature 
Communications, In Press. 
Cells – Cryopreserved PHH (PHH) were provided by QPS laboratories 
(Newark, NJ, USA) and Life Technologies (Carlsbad, CA, USA). Briefly, PHH 
were resuspended in prewarmed thawing medium (QPS laboratories). PHH 
were centrifuged at 100 × g for 10 min, and resuspended in Williams E 
medium (WEM) supplemented with Thawing/Plating Supplement Pack 
(Invitrogen, Paisley, UK) that consisted in 5% Fetal Bovine Serum (FBS), 1 
μM Dexamethasone, 100 IU/mL Penicillin, 100 μg/mL Streptomycin, 4 μg/ml 
Human Recombinant Insulin, 2 mM GlutaMAXTM and 15 mM HEPES, pH 7.4. 
Cell viability was determined using trypan blue (Sigma-Aldrich, Dorset, UK) 
and was above 90% in all cases.  
Microfluidic 3D culture system – Cells were seeded into isolated bioreactors 
within the LiverChip platform (CNBio Innovations, Welwyn Garden City, 
Hertfordshire, UK) with flow in the downward direction on top of collagen-
coated scaffolds for 8 hours at a flow rate of 1.0 μl/s. Following cell 
attachment within the scaffold, the flow was changed to the upward direction 
and maintained at 1.0 μl/s for the remainder of the culture. Hepatocyte 
monocultures were seeded at a density of 0.6x106 viable cells in 1.6 ml of 
medium per well. The cells were maintained in WEM supplemented with 
Thawing/Plating Supplement Pack (Invitrogen) for the first 24 hours of culture 
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and in WEM supplemented with Cell Maintenance Supplement Pack 
(Invitrogen) thereafter for the duration of the culture. The media was replaced 
every 48h.  
HBV patient-derived viruses and infections – HBV positive serum samples of 
four different donors were used at m.o.i. of 100 genome equivalents per cell. 
For the 3D infections, serum samples were diluted in 1.6 mL of WEM 
supplemented with Cell Maintenance Supplement Pack with dexamethasone 
or hydrocortisone (Invitrogen). HBV infection was performed 3 days after 
seeding for 24 hours, after which cells were washed three times with 
maintenance medium for 3.5 min using 1 μL/s downward flow. 2D infections 
were performed using PHH seeded in 24 well collagen-treated plates. 
Infections were carried out for 24 hours, after which cells were washed three 
times and medium was replaced with maintenance medium.  
2.15 HCC tissue slices 
For some experiments, ex vivo HCC tissue was used instead of cell lines. 
Cut pieces of HCC tissue were provided by the Tissue Access for Patient 
Benefit service (TAPb) at the Royal Free Hospital. A 5mm punch biopsy 
(Stiefel) was used to prepare cores or uniform diameter, from which 1mm 
slices were cut. Thin 5mm circles of HCC tissue were carefully placed in 
wells of round bottom 96 well microtitre plates and allowed to rest for four 
hours in CRPMI+8% FBS. Magnetic bead isolated NK cells were stained with 
Cell Trace Violet (Life Technologies) as per the manufacturer’s protocol 
before addition to the HCC slices as above. 
2.16 CD107a assays 
NK cells were mixed with K562 cells at 1:1 effector:target ratio in 200µl 
CRPMI+10% FBS in 96 well, round bottom plates (Sarstedt). Brefeldin to a 
final concentration of 1µg/ml (Sigma) and anti-CD107a V450 were added and 
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the plate centrifuged at 300rpm for 3 minutes before incubation at 37°C for 
three hours before staining for flow cytometry as above. 
2.17 Cytokine stimulation 
PBMC, intrahepatic and intra-tumour lymphocytes were stimulated with 
5ng/ml IL-12 and 50ng/ml IL-18, or 1ng/ml IL-15 for 12 hours in the presence 
of 1µg/ml brefeldin, before intracellular cytokine staining as above.  
2.18 Immunohistochemistry 
Formalin fixed, paraffin-embedded sections of paired tumour and liver tissue 
were dewaxed and rehydrated, and antigen retrieval performed as described 
previously (Dunn et al 2007). Endogenous peroxidase activity was quenched 
with 10% hydrogen peroxide (VWR) in PBS before blocking with 2.5% horse 
serum (Vector Labs). Anti-ULBP1 antibody (Santa Cruz Biotech) was applied 
at 1:200 in PBS with 1% BSA (Sigma) overnight at 4°C. Slides were washed 
and primary antibody detected with ImmPress Horseradish Peroxidase 
Polymer Detection Kit for 30 minutes. After further washes antibody was 
visualised by Impact DAB (Vector Labs), then counterstained with 
haematoxylin (Sigma) and dehydrated before mounting. 
2.19 Statistical analysis 
The Mann Whitney-U test was used for comparisons of two unpaired groups 
where n=6 or greater, unpaired t test with Welch’s correction was used for 
comparisons of smaller groups. The Wilcoxon signed rank test was used for 
comparisons of two paired groups. Spearman rank test was used for 
correlations of continuous variables. These tests were performed in 
GraphPad Prism version 6. 
Multiple linear regression and Poisson regression were performed in STATA 
(Statacorp) version 13. MANOVA was performed in SPSS (IBM) version 24. 
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P ≤0.05 was considered to be significant for all tests. Figures are labelled: *, 
p ≤0.05; **, p ≤0.005; ***, p ≤0.001; ****, p ≤0.0001 
2.20 Research Ethics Approval 
Blood and tissue sampling in Gambian patients was approved by the 
Scientific Coordinating Committee of the MRC Unit, The Gambia as 
SCC1379 and SCC1266. 
Blood and tissue sampling of UK patients was approved by the University 
College London-Royal Free Hospital Research Ethics Committee, ref nos. 
11/WA/0077 (liver explants), 11/H0720/4 (liver perfusates), 10/H0720/34 
(HCC serum cohort). Blood sampling from healthy donors was approved by 
the South East Coast Research Ethics Committee, ref no. 11/LO/0421.  
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 Table 2.1 List of reagents 
Reagent Cat No. Manufacturer 
MICA DuoSet ELISA kit DY1300 R&D 
MICB DuoSet ELISA kit DY1599 R&D 
ULBP1 DuoSet ELISA kit DY1380 R&D 
ULBP2 DuoSet ELISA kit DY1298 R&D 
ULBP3 DuoSet ELISA kit DY1517 R&D 
Phosphate buffered saline P4417-100TAB Sigma 
Tween-20 BP337-500 Fisher 
Fraction V BSA BP1605-100 Fisher 
Substrate reagents A+B DY999 R&D 
Stop Solution DY994 R&D 
Fc receptor blocking 130-059-901 Miltenyi Biotec 
BODIPY-FL B10250 ThermoFisher 
Cytofix 554655 BD 
Cytofix/cytoperm 554722 BD 
Phosflow Perm Buffer III 558050 BD 
DAPI D1306 ThermoFisher 
Ficoll-Hypaque 17-1440-02 GE Healthcare 
RPMI 11879-020 Gibco 
DNAase 11 284 932 001 Roche 
Collagenase 17104-019 ThermoFisher 
Percoll 17-0891-01 GE Healthcare 
Brilliant Stain buffer 566349 BD 
Trypan Blue T8154-100ML Sigma 
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Fixable live/dead aqua L34957 Life Technologies 
Fixable live/dead blue L23105 Life Technologies 
Saponin S-7900 Sigma 
Fetal bovine serum F9665-500ML Sigma 
DMSO D2650-100ML Sigma 
FoxP3 staining buffer 560098 BD 
CompBeads 51-90-9001229 BD 
Hepes 15630-056 Gibco 
MEM Essential amino acids 11130-036 Gibco 
MEM Non-essential amino acids 11140-035 Gibco 
Mercaptoethanol 31350-010 Gibco 
Sodium pyruvate 11360-039 Gibco 
Penicillin/Streptomycin 15140122 Gibco 
Amphotericin B A2942-100ML Sigma 
Trypsin-EDTA 25300-062 Gibco 
DMEM 61965-026 Gibco 
NK cell isolation kit 130-092-657 Miltenyi Biotec 
Recombinant human NKG2D 10575-H07B Sino Biological 
Anti-MICA MAB13001-100 R&D 
Recombinant human MICA 12302-H08H-25 Sino Biological 
Recombinant human ULBP1 10679-H08H-25 Sino Biological 
Anti-DNAM1 MAB666-100 R&D 
Anti-TGFβ receptor AF-241-NA R&D 
Anti-IL6 receptor α MAB277-100 R&D 
Anti-HLA ABC 311412 BioLegend 
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Recombinant human IL-15 247-IL R&D 
Recombinant human IL-2 130-093-903 Miltenyi 
Recombinant human IL-12 219-IL R&D 
Recombinant human IL-18 B001-5 MBL 
Recombinant human IFNα 11100-1 PBL Interferon 
EDTA E7889-100ML Sigma 
Brefeldin B6542 Sigma 
Hydrogen peroxide 101284N VWR 
2.5% Horse Serum MP-7402 Vector Labs 
Anti-ULBP1 sc-53131 Santa Cruz Biotech 
HRP Polymer Detection Kit MP-7402 Vector Labs 
Impact DAB SK-4105 Vector Labs 
Haematoxylin GHS332-1L Sigma 
Cell Trace Violet C34557 Life Technologies 
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Table 2.2 Antibodies for flow cytometry 
Target Clone Cat No. Manufacturer 
CD45 BUV805 HI30 564914 BD 
CD45 PE Cy7 HI30 25-0459-42 eBioscience 
CD56 PE-Cy7 NCAM16.2 335826 BD 
CD56 ECD N901 A82943 Beckman Coulter 
CD3 BV711 OKT3 317328 BioLegend 
CD3 PE-Cy7 UCHT1 25-0038-42 eBioscience 
CD3 BUV395 UCHT1 563546 BD 
CD3 PE-CF594 UCHT1 562280 BD 
CD16 APC-Cy7 3G8 557758 BD 
NKG2D Alexa 488 149810 FAB139G R&D 
NKG2D APC 1D11 320808 BioLegend 
NKG2C APC 134591 FAB138A R&D 
NKG2A Alexa 700 131411 FAB1059N R&D 
NKp46 BV605 9E2 331925 BioLegend 
NKp30 PE AF29-4D12 130-092-483 Miltenyi Biotec 
CXCR6 PE K041E5 356004 BioLegend 
CXCR6 BV421 K041E5 356014 BioLegend 
CXCR6 PE Dazzle K041E5 356016 BioLegend 
CXCR6 APC K041E5 356006 BioLegend 
HLA-DR e450 L243 48-9952-42 eBioscience 
HLA-DR V500 G46-6 561224 BD 
CD69 PE Dazzle FN50 310942 BioLegend 
CD69 BV605 FN50 310938 BioLegend 
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CD69 BV785 FN50 310932 BioLegend 
IFNγ BV605 4S.B3 502535 BioLegend 
IFNγ FITC 25723 IC285F R&D 
CD107a V450 H4A3 560647 BD 
CD57 e450 TB01 48-0577 eBioscience 
CD57 FITC TB01 11-0577-42 eBioscience 
CD8 Alexa 700 OKT8 56-0086-82 eBioscience 
CD8 BV785 RPA-T8 301045 BioLegend 
Perforin PerCP Cy5.5 dG9 308113 BioLegend 
Perforin APC Cy7 dG9 308128 BioLegend 
CD25 APC-eFluor780 BC96 47-0259-42 eBioscience 
Granzyme B Alexa 700 GB11 560213 BD 
ULBP1 PE 170818 FAB1380P R&D 
ULBP2/5/6 APC 165903 FAB1298A R&D 
ULBP3 PE 166510 FAB1517P R&D 
MICA/B PE 6D4 558352 BD 
PVR PE Cy7 SKII.4 337614 BioLegend 
Nectin-2 APC TX31 337412 BioLegend 
HLA-ABC PE Cy7 W6/32 25-9983-42 eBioscience 
HLA-E APC 3D12HLA-E 17-9953-42 eBioscience 
Ki67 FITC B56 556026 BD 
Caspase 3 PE C92-605 550821 BD 
MCL-1 PE D2W9E 65617S Cell Signalling 




Chapter 3 Serum NKG2D ligands in HCC and CHB 
3.1 Introduction 
The Prevention of Liver Fibrosis and Cancer in Africa (Prolifica) study, led by 
Prof Mark Thursz at Imperial College London and funded by the EU, consists 
of two clinical cohorts and a platform for laboratory investigation of liver 
disease in West Africa. The first clinical cohort, the West African Treatment 
Cohort for Hepatitis B (WATCH), consists of patients screened for HBsAg by 
point of care test in the Western region of The Gambia (Lemoine et al. 2016). 
The study team visited 54 randomly chosen census enumeration areas, 27 
rural and 27 urban, and individuals over 30 years of age were offered HBsAg 
testing (the national hepatitis B vaccination programme commenced in 1990). 
Individuals who tested positive were offered full clinical assessment (clinical 
examination, liver function tests, liver ultrasound, fibroscan and HBV DNA 
viral load measurement) at the MRC Fajara liver clinic. In addition, some 
HBsAg negative participants received clinical assessment in order to 
establish normal ranges and to act as controls. A number of additional 
patients were added following HBsAg testing before blood donation at 
Edward Francis Small Teaching Hospital, as well as a small number of cases 
in Keneba and Manduar, the villages where the first hepatitis B vaccination 
studies were performed (Whittle et al. 2002). Treatment of cases here as 
soon as HBV treatment was offered in The Gambia was a condition of the 
original studies. Patients were treated with tenofovir according to EASL 2012 
guidelines (European Association for the Study of the Liver 2012). HBeAg 
was not routinely performed as this is not required to make treatment 
decisions. 
The second clinical study, the Hepatocellular Carcinoma Case-Control study 
(HC4), involved clinical assessment (as for WATCH) of patients referred to 
the Fajara liver clinic with suspected liver disease or HCC. Individuals were 
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referred from a number of surrounding medical facilities with symptoms 
including jaundice, ascites, abdominal mass. Patients were also recruited to 
HC4 in Senegal and Nigeria, but all the data in this work relates to patients 
recruited at MRC Unit The Gambia, Fajara. Patients were recruited before 
clinical assessment, so this cohort contained patients with HCC and with a 
range of other diagnoses (liver cirrhosis, active hepatitis B, other abdominal 
malignancy or liver mass, congestive cardiac failure) in order to establish risk 
factors for HCC in West Africa. 
Diagnosis of HCC was based on histology in some cases, and in others a 
combination of liver mass on ultrasound, relevant risk factor for HCC and 
positive alphafetoprotein (AFP). Where biopsy was not performed, it is 
difficult to distinguish between AFP-negative HCC and a liver mass with an 
alternate diagnosis as ultrasound has a poor specificity. Unfortunately, AFP 
has a poor sensitivity, so there will have been a number of true HCCs in this 
group (T.-S. Chang et al. 2015).  
It is known that NK cells can have multiple roles in CHB and cancer (Maini & 
Peppa 2013; Morvan & Lanier 2016). In Asia, the soluble form of the NKG2D 
ligand MICA has been associated with improved prognosis in HCC, whereas 
cell surface expression of ULBP1 (but not MICA) was associated with 
improved recurrence-free survival (Kamimura et al. 2012). However there 
was a strong correlation between soluble MICA in the periphery and vascular 
invasion of the tumour (Kumar et al. 2012). MICA in this setting may not have 
a causative effect on survival, and may instead be confounded by some other 
consequence of vascularity. I set out to survey soluble NKG2D ligands in a 
cohort of hepatitis B-associated HCC and CHB patients in Africa, to 
investigate what process is likely to be driving their release, whether soluble 
NKG2D ligands influence survival in this setting and whether alterations to 
NK cells are likely to contribute to this effect. 
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3.2 Hypothesis and research questions 
Hypothesis: HCC secretes NKG2D ligands into the circulation and these 
ligands affect survival via an effect on NK cell anti-tumour function mediated 
by NKG2D. 
1. Which soluble NKG2D ligands are released by hepatitis B-associated 
HCC? 
2. Does soluble ligand release affect NKG2D expression by circulating NK 
cells and if so, does this impact effector function? 
3. Does NKG2D ligand expression have prognostic association and are these 
independent of disease staging and other known prognostic markers? 
4. Is NKG2D ligand expression related to the aetiology of the HCC? 
5. Is soluble NKG2D ligand expression seen in secondary liver tumours? 




3.3 Patient cohort 
Demographic and clinical data for this cohort is shown in Table 3.1. Patients 
were grouped according the criteria in Table 3.2. Cut-off values for viral load 
and ALT were the same as those used for clinical management. Note that 
some of my groups, particularly the cirrhosis and active CHB groups, patients 
have been included from both WATCH and HC4. The active CHB will contain 
both HBeAg positive chronic hepatitis and HBeAg negative chronic hepatitis 
patients. Management is similar in both disease stages. Similarly the 
cirrhosis group contains a range of disease activities, but is an important 
comparator for the HCC patients. 
  
Parameter CHB HCC Healthy control
Male:Female 
ratio


























Table 3.1 Demographic and clinical characteristics of the 
CHB, HCC and control cohorts
Median (range) for age, HBV DNA viral load, alanine transaminase (ALT), 
platelet count and albumin of the chronic hepatitis B (CHB), hepatocellular 
carcinoma (HCC) and healthy control groups. Student’s t-test with Welch’s 





3.4.1 Soluble ULBP1 is found in the serum of patients with HCC and 
active HBV 
Serum from a cohort of patients with HBV-associated HCC, CHB in various 
clinical stages and controls was screened for the NKG2D ligands MICA, 
MICB, ULBP1, ULBP2 and ULBP3 (Fig 3.1 A-E). Sporadic individuals had 
detectable amounts of MICA and MICB, but there were no consistent 
differences between clinical groups. Very few were positive for ULBP2 or 
ULBP3 (Fig 3.1 A, B, D, E). However serum ULBP1 concentrations showed a 
clear, stepwise increase from inactive to active and cirrhotic CHB to HCC 
(Fig 3.1 C). Controls and patients with inactive CHB had low and similar 
levels of ULBP1, whereas these were significantly raised in patients with 
active CHB (defined as ALT>80 IU/ml or HBV DNA >2000 IU/ml) and in 
those with cirrhosis (median liver stiffness >10kPa or histologically proven 
cirrhosis). HCC patients had significantly higher levels of ULBP1 than all the 
CHB groups, with only 2 out of 34 individuals in this group below the limit of 
detection.  
NKG2D ligands in serum may be present as soluble protein, either as a result 
of proteolytic cleavage or alternative splicing, or on circulating exosomes. 
This may affect their activity as multi-valent exosomes can more readily 
cross-link NKG2D than individual soluble proteins, leading to NKG2D 
downregulation on NK cells and impaired cytotoxicity (Fernández-Messina et 
al. 2010; Ashiru et al. 2010; Labani-Motlagh et al. 2016). In a subset of 
patients with high ULBP1 levels, serum was separated by size exclusion 
chromatography into exosome and protein fractions. ULBP1 concentrations 
were similar in the whole serum and protein fractions and significantly lower 
in the exosome fraction (Fig 3.2 A). The presence of exosomes in the 
exosome fraction was confirmed by staining of membranous bodies with 
BODIPY-FL and visualisation by imaging cytometry (Fig 3.2 B).  
Clinical Group Criteria
HCC HBsAg positive, HCC on histology or liver 
mass on USS and raised AFP
CHB Cirrhosis HBsAg positive, MLS >10kPa or cirrhosis on 
histology
Active CHB HBsAg positive, VL >2000 IU/ml or ALT >80 
IU/ml
Inactive CHB HBsAg positive, VL<2000 IU/ml, ALT<80 IU/ml
Negative control HBsAg negative
Apart from the negative control group, all patients included in the NKG2D 
ligand serum survey were HBsAg positive. USS, ultrasound scan; MLS, 
median liver stiffness calculated by fibroscan; VL, hepatitis B virus DNA viral 
load in plasma. 































































































































































Figure 3.1 ULBP1 is elevated in the serum of individuals with HCC or advanced CHB 
disease
To form a holistic assessment of soluble NKG2D ligand expression in HCC and CHB, serum 
concentrations of soluble NKG2D ligands were measured by sandwich ELISA in five partici-
pant groups – HCC (HBV associated HCC), Cirrhosis (HBV associated cirrhosis defined as 
median liver stiffness >10kPa or biopsy-proven liver cirrhosis), Active (HBV without HCC or 
cirrhosis but with viral load >2000 IU/ml or ALT >80 U/l), Inactive (HBV without HCC, Cirrho-
sis, raised HBV viral load or raised ALT) and Negative control (HBsAg negative). Data shown 
for A. MICA (n=178), B. MICB (n=132), C. ULBP1 (n=177), D. ULBP2 (n=133), E. ULBP3 
(n=181). Grey dotted lines indicate the limit of quantitation. Values below limit of quantitation 
were set to zero before statistical analysis by Mann-Whitney U test. P ≤0.05 was considered 




ULBP1 was demonstrated on a small proportion of exosomes, which were 
CD45 negative (Fig 3.2 C). This suggests that the majority of soluble ULBP1 
in serum is present as soluble protein, rather than being expressed on a 
membranous body, although it is possible that some ULBP1 is shed by HCC 
on tumour exosomes. 
3.4.2 Soluble ULBP1 does not affect NK cells 
Other soluble NKG2D ligands, notably MICA, have been shown to impair NK 
cell function. To investigate whether serum ULBP1 had an affect on NK cell 
function, we first looked at NKG2D expression ex vivo by flow cytometry. 
NKG2D expression on both NK cells and CD8 T cells was not affected by 
either disease stage or by the presence of ULBP1 (Fig 3.3 A, B). In line with 
this ex vivo finding, recombinant human ULBP1 also did not affect NKG2D 
expression on NK cells when added in vitro, even at high concentrations (Fig 
3.3 C). 
3.4.3 In CHB, soluble ULBP1 is associated with viraemia 
We looked at a number of clinical parameters that might drive ULBP1 
production in the CHB cohort. There was no association between ULBP1 and 
sex or age amongst CHB patients (Fig 3.4 A, B). In keeping with the 
observation that ULBP1 is associated with active CHB, there was a 
correlation between HBV DNA viral load and ULBP1 levels (Fig 3.4 C). 
Taking the clinically-relevant cut-off of 2000 IU/ml, there was a highly 
significant difference between the ULBP1 levels of patients with high and low 
level viraemia (Fig 3.4 D). There was also a statistically significant 
association between serum ALT and ULBP1 concentrations in a univariate 
analysis. In keeping with the lack of significant difference between ULBP1 
levels in cirrhotic CHB and active CHB without cirrhosis (Fig 3.1 C), there 
was no association between ULBP1 and three markers of cirrhosis: median 






































































































Figure 3.2 Serum ULBP1 is predominantly present as free protein rather than on 
exosomes
A. Serum was separated into exosome and protein fractions by size exclusion column 
filtration and ULBP1 concentration assessed by ELISA as in fig 1 (n=16). Groups were 
compared using Wilcoxon matched-pairs signed rank test. 
B. Imaging cytometry of whole serum, protein and exosome fractions stained with 
BODIPY-FL and anti ULBP1-PE. Small events are then gated on BODIPY positive to find the 
exosomes, a proportion of which are ULBP1 positive.
C. Representative images of ULBP1 positive and negative exosomes from the serum of an 
HCC patient.
P ≤0.05 was considered to be significant for all tests. Figures are labelled: *, p ≤0.05; **, p ≤
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Figure 3.3 ULBP1 in serum does not affect the expression of NKG2D by NK cells or 
CD8 T cells.
A. NKG2D expression by flow cytometry and presented as MFI of Alexa 488 NKG2D on 
total NK cells (n=54) and CD8 T (n=51) cells in peripheral blood of individuals with HCC, 
HBV-associated cirrhosis and inactive CHB. Mean and SEM shown.
B. NKG2D expression by flow cytometry and presented as MFI of Alexa 488 NKG2D on 
total NK cells (n=48) and CD8 T (n=47) cells in peripheral blood of individuals with 
positive serum ULBP1 (above the limit of detection) and negative serum ULBP1. Mean 
and SEM shown.
C. NKG2D expression by flow cytometry on total NK cells from two healthy donors 
following 6 hour incubation with recombinant ULBP1 at increasing concentrations.
P ≤0.05 was considered to be significant for all tests. Figures are labelled: *, p ≤0.05; **, 
p ≤0.005; ***, p ≤0.001; ****, p ≤0.0001.
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 analysis only viral load was found to be independently predictive of ULBP1 
expression (Table 3.3). In a subset of patients, serum was available before 
and after 12 months of antiviral treatment with tenofovir. In this cohort the 
ULBP1 concentration fell significantly after treatment, which supports the 
association between viral replication and serum ULBP1 (Fig 3.4 F). 
Using an in vitro model we investigated whether soluble ULBP1 release was 
due to a cell-intrinsic effect of HBV replication within hepatocytes. HepG2 
AD38 and HepG2.117 are cell lines transfected with full-length HBV 
genomes under Tet-off promoters, so culture with doxycycline suppresses 
HBV replication. They secrete HBV virions at high and low titre respectively. 
ULBP1 was not seen in the culture supernatant of either cell line. HepG2 
NTCP cells are HepG2 cells transfected with sodium taurocholate 
cotransporting peptide (NTCP), a bile transporter that is also the entry 
receptor for the HBV virion. This cell line is permissive for HBV infection but 
produces only very low numbers of viral particles. ULBP1 was detected at 
low level in 3 of 6 HBV infected HepG2 NTCP supernatants (Fig 3.5 B). 
Infection of primary human hepatocytes with HBV isolates from patients did 
not affect ULBP1 production, which was seen at high levels in both infected 
and uninfected cultures (Fig 3.5 C). 
3.4.4 In HCC, soluble ULBP1 is independent of viraemia and has 
prognostic significance 
In the HCC cohort, serum ULBP1 concentration was not correlated with HBV 
DNA viral load or serum ALT (Fig 3.6 A), or with markers of cirrhosis (serum 
albumin or platelet count, Fig 3.6 B) Median liver stiffness is not a measure of 
fibrosis/cirrhosis in this setting as the stiffness of the tumour exceeds that of 
the liver. Tumour volume can be estimated from the two linear dimensions 
reported on ultrasound scan of the liver(Sapi et al. 2015). Using this 
approach, ULBP1 was not associated with tumour volume (Fig 3.6 C). 



















































































Figure 3.4 In CHB, ULBP1 is associated with HBV replication and falls following 
treatment
A. Serum ULBP1 concentrations measured by ELISA in male and female individuals with 
CHB (n=111).
B. Serum ULBP1 concentrations measured by ELISA in the CHB individuals against age 
(n=111). 
C. Serum ULBP1 concentrations measured by ELISA in the CHB individuals against log10 
HBV DNA concentration (n=111). 
D. Serum ULBP1 concentration measured by ELISA for the CHB individuals (Cirrhosis, 
Active and Inactive) grouped by viral load above and below 2000 IU/ml (n=111).
E. Serum ULBP1 concentrations measured by ELISA in the CHB individuals against log10 
serum ALT concentration (n=113). 
F. Serum ULBP1 concentrations measured by ELISA at baseline (M0) and after 12 months of 
treatment with tenofovir (M12) (n=50). 
Groups compared using Wilcoxon matched-pairs signed rank test (paired) and Mann-Whit-
ney U test (unpaired). P-values for correlations calculated by Spearman nonparametric 
correlation. P ≤0.05 was considered to be significant for all tests. Figures are labelled: *, p ≤
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Figure 3.5 ULBP1 is not associated with markers of fibrosis, and is not produced by in 
vitro HBV replication
A. Serum ULBP1 concentrations measured by ELISA in individuals with HBV-associated liver 
cirrhosis against median liver stiffness (n=87), serum albumin concentration (n=55) and 
platelet count (n=56). P-value calculated by Spearman nonparametric correlation.
B. ULBP1 concentration measured by ELISA in 3-day culture supernatant from HepG2 AD38 
(n=3 for each group) and HepG2.117 (n=3 for each group) cells with and without doxycycline 
(inhibitor of HBV gene expression), and from HBV infected and control HepG2 NTCP cells 
(n=6 for each group). Mean and SEM shown. ND, not detected.
C. ULBP1 concentration measured by ELISA in supernatant from HBV infected and paired 
control primary human hepatocyte cultures (n=4 for each group). Mean and SEM shown.
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ND ND ND ND ND
Parameter Coefficient Standard 
Error
p value 95% 
confidence 
interval
ALT -1.7 3.02 0.593 -7.62 - 4.38
Log HBV 
DNA
302.0 65.47 >0.0001 172.0 - 431.9
Age 0-40 
years
0 - - -
Age 41-60 
years
477.8 296.7 0.111 -111 - 1067
Age 61+ 
years
1553 452.5 0.001 655.0 - 2451
Female 0 - - -
Male -394.8 300.5 0.192 -991.4 - 
201.7
Table 3.3 Multivariate analysis of predictors of serum 
ULBP1 concentration in CHB patients
Coefficient represents the predicted change in serum ULBP1 
concentration (pg/ml) of an increase in one unit of the named 
parameter (1IU ALT or 1 log HBV DNA) or with reference to the 
base group (age, male vs female). Coefficient, standard error, 




We sought to understand whether soluble ULBP1 production was a property 
of all intrahepatic tumours or just of hepatitis B-associated HCC. ULBP1 
concentrations were much higher in the serum of patients with HBV-
associated HCC compared with patients with secondary liver tumours of 
various causes (cholangiocarcinoma, lymphoma, metastatic pancreatic and 
colorectal cancer) (Fig 3.7 A). To confirm ULBP1 release direct from HCC, 
small pieces of tumour were weighed and incubated for 18 hours in 10x their 
mass of cell culture medium. Conditioned media was removed and 
centrifuged to remove all cells and debris before ELISA. ULBP1 was 
detectable in conditioned media and ULBP1 concentrations were higher in 
HCC conditioned media than in conditioned media from metastases of 
colorectal cancer (CRC) (Fig 3.7 B). In a UK-based cohort of HCC of various 
causes, there was no difference in soluble ULBP1 concentrations between 
HCC caused by HBV, HCV or other causes (Fig 3.7 C). This suggests that 
HCC, irrespective of aetiology, drives ULBP1 expression. ULBP1 levels were 
lower in HCC patients from the UK than from the Gambia (Fig 3.7 D), which 
may be indicative of a clinical difference between these groups.  
There was a strong association between serum ULBP1 concentration and 
survival. When ULBP1 concentration at first clinic visit was plotted against 
time from first clinic visit to death, a negative association was seen, indicating 
high ULBP1 concentration is associated with short survival (Fig 3.8 A). This 
may account for the difference between the ULBP1 concentrations in 
Gambian and UK patients, as patients in The Gambia tend to present late 
and have very poor prognosis, median survival in this cohort was 34 days. 
Comparing ULBP1 concentrations above and below 2000pg/ml, the Kaplan-
Meier curves showed a highly significant difference in survival (Fig 3.8 B), 
with a median survival of 76 days in the 0-2000pg/ml group and 22 days in 
the >2000pg/ml group. Other parameters known to have prognostic 
significance in HCC include age, serum albumin, bilirubin, alkaline 
phosphatase, tumour volume, the presence of ascites, and WHO 
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Figure 3.6 In HCC, ULBP1 is not associated with viral replication or tumour burden
A. Serum ULBP1 concentrations measured by ELISA in individuals with HCC against log10 
HBV DNA concentration (n=34) and log10 serum ALT concentration (n=31). 
B. Serum ULBP1 concentrations measured by ELISA in individuals with HCC against serum 
albumin (n=33) and platelet count (n=34). 
C. Serum ULBP1 concentrations measured by ELISA in individuals with HCC against tumour 
volume, estimated by calculating the volumes of spheroids with dimensions measured by 
liver ultrasound scan (n=27). 




















































































Figure 3.7 ULBP1 is present at high levels in serum from HCC patients but not in 
serum from secondary liver cancer patients
A. Serum ULBP1 concentration measured by ELISA in HBV-associated HCC (n=34), and 
non-HCC secondary tumours within the liver (n=8). 
B. ULBP1 concentration measured by ELISA in overnight conditioned media from CRC and 
HCC tissue (n=2 in each group).
C. Serum ULBP1 concentration measured by ELISA in HBV-associated HCC (n=8), HCV-as-
sociated HCC (n=18) and HCC of other causes (n=45), all from a UK cohort. 
D. Serum ULBP1 concentration measured by ELISA in HCC patients from The Gambia 
(n=34), and from the UK (n=71).
Groups compared by Mann-Whitney U test. P-values for correlations calculated by Spear-
man nonparametric correlation. P ≤0.05 was considered to be significant for all tests. Figures 












































Figure 3.8 Serum ULBP1 predicts survival with HCC in The Gambia
A. Soluble ULBP1 measured by ELISA at baseline clinical assessment in individuals with 
HCC plotted against survival (n=29). P-value for correlation calculated by Spearman nonpar-
ametric correlation.
B. Kaplan-Meier curves comparing survival from the day of baseline clinical assessment 
between groups with serum ULBP1 concentration measured by ELISA above and below 
2000pg/ml. P-value for difference calculated by log-rank test.
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performance status (op den Winkel et al. 2012; Hsu et al. 2013). In univariate 
analysis, ULBP1>2000pg/ml had a hazard ratio for death of 3.65, 
comparable to that of bilirubin, albumin and ascites (Table 4). WHO 
performance status of 2 or greater and Okuda stage 3 (Okuda et al. 1985) 
were also positively associated with mortality, consistent with other cohorts. 
Age and sex did not have a significant effect on prognosis, which was poor 
among all demographic groups. 
We used Poisson regression to compare prediction models with and without 
ULBP1 concentration. ULBP1 was an independent predictor of survival in this 
cohort when age, sex, WHO performance status and Okuda stage (a clinical 
scoring system incorporating ascites, albumin, bilirubin and disease burden) 
were accounted for (Table 5), suggesting that serum ULBP1 measurement 
gives additional prognostic information not captured by these other 
measures. In an alternative model separately incorporating ULBP1, age, sex, 
simplified WHO performance status, bilirubin, albumin and ascites showed no 
significant associations with survival (the large number of covariates 
decreasing statistical power), but ULBP1 had a hazard ratio less than that of 
bilirubin but comparable to ascites, albumin and performance status (Table 
6). 
  
Parameter and cutoff Hazard ratio p value
Bilirubin >50μmol/l 5.18 (1.934 - 
13.873)
0.0003
ULBP1 >2000pg/ml 3.65 (1.687 - 
7.883)
0.0004
Albumin ≤30g/dL 3.46 (10479 - 
8.076)
0.0023
Ascites 2.66 (1.229 - 
5.745)
0.0098
Alkaline phosphatase >150IU/L 2.38 (0.889 - 
6.373)
0.075
WHO performance status 2+ 2.73 (1.193 - 
6.227)
0.017
Okuda stage 1 1 -
Okuda stage 2 1.43 (0.583 - 
3.528)
0.433
Okuda stage 3 4.19 (1.403 - 
12.493)
0.010
Age 0-40 1 -
Age 41-60 0.59 (0.263 - 
1.304)
0.190
Age 61+ 2.44 (0.323 - 
18.495)
0.387
Female sex 1.804 (0.677 - 
4.805)
0.231
Table 3.4 Univariate associations with mortality in HBV-
associated HCC patients
Hazard rate ratio for death and p value calculated by linear regression for 
ULBP1 and a range of clinical parameters. WHO performance status was 
grouped into 0-1 and 2-4. Ascites was defined by ultrasound.
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p value Hazard 
ratio in 
multivariate
p value in 
multivariate
ULBP1 >2000 3.65 
(1.69-7.88)
0.0012 5.23 (1.49 - 
18.37)
0.01
Okuda stage 1 1
0.066Okuda stage 2 1.43 (0.58-3.53)






0.015 1.66 (0.63 - 
4.38)
0.309
Age 0-40 years 1
0.26
1
0.85Age 41-60 years 0.58 (0.26-1.3)
1.36 (0.46 - 
4.07)
Age 61+ years 2.44 
(0.32-18.50)




0.27 0.48 (0.14 - 
1.63)
0.24
Table 3.5 Multivariate analysis of mortality in HBV-
associated HCC, incorporating Okuda stage 
Hazard rate ratio for death and p value calculated by linear 
regression for ULBP1 and a range of clinical parameters. 
Parameters with an overall p value <0.05 as well as age and 
sex were taken forward into a Poisson regression model to 
calculate multivariate hazard rate ratios for death and 
associated p values.
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p value Hazard ratio 
in 
multivariate
p value in 
multivariate
ULBP1 >2000 3.65 
(1.69-7.88)
0.0012 1.78 (0.4 - 
8.00)
0.45
Bilirubin >50μmol/l 5.18 (1.934 - 
13.873)
0.0003 3.02 (0.76 - 
11.95)
0.12
Ascites 3.46 (10479 - 
8.076)
0.0023 1.68 (0.44 - 
6.08)
0.94
Albumin ≤30g/dL 2.66 (1.229 - 
5.745)







0.015 1.6 (0.42 - 
6.08)
0.49
Age 0-40 years 1
0.26
1
0.73Age 41-60 years 0.58 (0.26-1.3)
0.74 (0.19 - 
2.82)
Age 61+ years 2.44 
(0.32-18.50)







Table 3.6 Multivariate analysis of mortality in HBV-
associated HCC, incorporating ascites, bilirubin and 
albumin
Hazard rate ratio for death and p value calculated by linear 
regression for ULBP1 and a range of clinical parameters. 
Parameters with an overall p value <0.05 as well as age and 
sex were taken forward into a Poisson regression model to 





Previous work on soluble NKG2D ligands in HCC has focused on MICA. We 
present the first survey of MICA, MICB, and ULBP 1, 2, 3. Due to the 
sequence homology between ULBPs 2, 5 and 6, the ULBP2 ELISA also 
detects ULBP5 at 0.5% cross-reactivity and ULBP6 at 27.9% cross-reactivity. 
As ULBP2 was undetectable in 129 of 133 individuals it is unlikely that 
ULBP5 or 6 are present in significant amounts in the serum of CHB or HCC 
patients. This is also the first study of NKG2D ligands outside of Asia. 
Previous series from Japan (Kumar et al. 2012) and China (J.-J. Li et al. 
2013) demonstrated the presence of soluble MICA in a proportion of 
individuals with HCC, and that this ligand was associated with a poor 
prognosis. Similar mechanisms have been shown for MICA in prostate (Wu 
et al. 2004) and colorectal cancer (Doubrovina et al. 2003) and for ULBP2 in 
ovarian cancer (K. Li et al. 2008) and malignant melanoma (Paschen et al. 
2009). 
Our patient cohort was nested within the Prolifica study, which incorporates a 
community screened cohort of chronic hepatitis B (CHB) patients over 30 
years of age (Lemoine et al. 2016) and a cohort of individuals referred with 
signs and symptoms of liver disease, who were assessed for HCC. Hepatitis 
B negative controls were derived exclusively from the community screening, 
and were older than either of the disease groups, possibly because older 
individuals were more willing to attend the MRC Unit. Compared to the CHB 
cohort, the HCC group was older, with similar HBV DNA viral load and ALT 
but with a higher platelet count and lower albumin, likely indicative of a 
catabolic and inflammatory response to the tumour (Porporato 2016; Carr & 
V. Guerra 2013). 
In this cohort of patients with hepatitis B from The Gambia, elevated MICA 
was observed in only a small number of individuals with HCC. By contrast 
ULBP1 was elevated in almost all of our cohort with HBV-related HCC. 
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ULBP1 was also raised, to a lesser extent, in the serum of CHB patients with 
cirrhosis or active hepatitis B disease without HCC. Overall ULBP1 levels 
were similar between hepatitis B-negative controls and those with inactive 
hepatitis B, effectively dividing the five clinical categories into three groups by 
ULBP1: HCC; cirrhotic and active CHB; inactive CHB and HBV negative 
individuals. 
NKG2D ligands can be expressed and released from cells in a variety of 
ways, which may have consequences for NKG2D signalling and downstream 
functional responses (Raulet et al. 2013). In particular NKG2D ligands shed 
on exosomes have the potential to modulate NK cell lytic function. In this 
cohort, ULBP1 was not shed primarily as exosomes but as soluble protein. 
This may explain the lack of effect on NKG2D expression on ex vivo NK cells 
and CD8 T cells, supported by the preservation of NKG2D on the surface of 
NK cells in the face of increasing concentrations of recombinant human 
ULBP1. This is in contrast to the impairment of NKG2D expression and 
function seen in settings of soluble MICA (Groh et al. 2002; Jinushi et al. 
2005). It is known that ULBP2 is a weaker downregulator of NKG2D on NK 
cells than MICA despite similar binding affinities, the explanation for this is 
unclear, and may be related to the spatial organisation of receptor 
microclusters (Molfetta et al. 2014). 
In chronic hepatitis B disease, NK cells may play multiple roles - reviewed in 
(Maini & Peppa 2013). NK cells may contribute to viral control by killing 
infected hepatocytes (Dunn et al. 2007), may inhibit fibrosis by killing 
intrahepatic stellate cells (Glassner et al. 2012), and can modulate T cell 
responses via TRAIL (Peppa et al. 2013) and NKG2D (W.-C. Huang et al. 
2017). In most cases these effects are most pronounced in patients with 
active inflammation. Although ALT is positively correlated with ULBP1 
concentration, in multivariate analysis only HBV DNA viral load and age over 
61 years were independently associated with ULBP1, and specific antiviral 
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treatment that inhibits viral replication within 12 months reduces serum 
ULBP1 (Gordon et al. 2013). It is unclear why advanced age is associated 
with raised ULBP1, especially as when considered as a continuous variable 
there is no significant correlation. It may be that older individuals are more 
likely to have microscopic or preclinical hepatomas and are therefore 
behaving like individuals in the HCC group. Alternatively it may be an effect 
of the unusual clinical course of CHB, where a high viral load in young and 
old individuals may represent different disease stages (Rehermann & 
Nascimbeni 2005).  
HBV replicating hepatoma cell lines do not release significant amounts of 
ULBP1, suggesting that ULBP1 may not be produced as a direct 
consequence of HBV infection of hepatocytes. It may be that interaction with 
another cell type is required to induce ULBP1 production in response to HBV 
replication, and this may also explain the wide variation in serum ULBP1 
even in those patients with elevated HBV DNA viral load. Alternatively this 
may be a consequence of the relatively low level of viral replication seen in 
even the best in-vitro culture systems compared to the in vivo state. 
Interestingly, primary human hepatocytes secreted soluble ULBP1 
irrespective of HBV infection, which may be indicative of some cellular stress 
related to the specialised culture system required to maintain these cells 
(March et al. 2015). 
By contrast to CHB, in HCC HBV DNA viral load is not a predictor of ULBP1 
concentration, neither is ALT, tumour size or any of the measures of fibrosis. 
This is somewhat surprising – in Li et al there was an association between 
soluble MICA and tumour size (J.-J. Li et al. 2013) and in Kumar et al 
between MICA and tumour vascularity (Kumar et al. 2012). We were unable 
to consider tumour vascularity as we did not have access to Doppler 
ultrasound, but were able to estimate tumour volume as spheroids from two-
dimensional ultrasound measurements, and over a wide range of volumes 
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there was no association with ULBP1 concentration. This may be because 
HCC presents late, with advanced disease in Africa (Gyedu et al. 2014). As a 
result patients with very large tumours often have large, single, slow growing 
lesions that may be less aggressive. It is unclear what the driver of this HBV-
independent ULBP1 production is in HCC, it may be driven by integration of 
HBV genomes in HCC cells, leading to the dissociation of ULBP1 from HBV 
viral load, but we were not able to see evidence to support this in transfected 
HepG2 cells (Fig 3.5 B). Indeed, in a cohort of HCC patients with various 
aetiologies from the UK, raised ULBP1 was seen in HBV-associated, HCV-
associated and non-viral HCC, suggesting HBV infection is not required to 
drive ULBP1 expression (Fig 3.7 C). ULBP1 was seen only at very low levels 
in non-HCC liver tumours in the Gambia, suggesting that the very high levels 
of ULBP1 seen in this cohort may not be due to an ethnic or local exposure 
effect or simply due to hepatocyte destruction and instead that soluble 
ULBP1 is associated with malignant hepatocytes. ULBP1 was detectable in 
conditioned media from HCC and CRC, but at a higher level in HCC, 
confirming this specificity. 
It may be that in CHB, active or cirrhotic disease results in microhepatoma 
formation (Mason et al. 2016), which results in ULBP1 production, and that 
other active liver diseases may have similar effects. 
ULBP1 was strongly associated with survival (Fig 3.8 A, B). Serum ULBP1 
concentration >2000pg/ml was associated with a median survival of 22 days, 
compared with 76 days where ULBP <2000pg/ml. In univariate analysis the 
hazard rate ratio for death was 3.65 for HCC patients with 
ULBP1>2000pg/ml. This effect was independent of age, sex, Okuda stage or 
simplified WHO performance status (WHO performance status on a 0-5 scale 
was not significantly associated with survival in univariate analysis) in a 
Poisson regression model. In a large study of prognostic indicators in a 
cohort from Germany, Okuda staging was shown to be a good 
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prognostication method, and no single parameter had a hazard ratio for 
death above 1.7 (op den Winkel et al. 2012). Many of the German patients 
had some form of treatment, so there will be significant differences between 
the two cohorts. However, in univariate analysis the parameters associated 
with mortality were very similar (bilirubin, albumin, ascites), and the hazard 
ratio for death for ULBP1 was comparable to these well recognised 
prognostic markers, indicating that ULBP1 may be a clinically useful 
prognostic marker in advanced HCC. The highest concordance index for any 
method of HCC prognostication in this German cohort was 0.71 (values for 
concordance index range from 0.5-1), indicating some factors affecting 
prognosis are not captured in any of the available clinical scores. It was not 
possible to compare sULBP1 concentrations across histological grades as 
only a minority of patients had a tissue diagnosis – most HCC diagnoses 
both in the UK and in the Gambia were made on the basis of characteristic 
radiological features so histological grading is unavailable in most cases. To 
demonstrate the generalisibility of the association between serum ULBP1, 
work is underway to gather survival data from the UK cohort so that 
outcomes with high and low serum ULBP1 can be compared as for the 
Gambian cohort. A larger study of ULBP1 in HCC prognostication with a 
range of disease stages and grades will be required to assess whether this 
marker may be of clinical utility in this setting. It would be particularly 
important to ascertain whether elevated ULBP1 in CHB (or other liver 
diseases) is predictive of future HCC, or whether ULBP1 screening may 
improve on AFP as an early biomarker for HCC. 
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Chapter 4 NK cells infiltrating primary and secondary liver 
tumours 
4.1 Introduction 
NK cells are capable of providing both tumour surveillance and tumour 
immunity (Morvan & Lanier 2016). However, for a tumour to become clinically 
apparent, these protective mechanisms must have failed. If we could 
understand why NK cells fail to clear certain malignancies it might be 
possible to intervene, to re-activate NK cell-mediated tumour immunity as a 
form of cancer therapy. This might be of particular use in the liver, where NK 
cells are plentiful and both primary and secondary tumours are common. 
The NKG2D receptor-ligand system is one of the best characterised of the 
activating NK cell receptors. NKG2D ligands are known to be expressed on 
HCC and colorectal tumours, where their loss is associated with a poor 
prognosis (Kamimura et al. 2012; McGilvray et al. 2009). Although NKG2D 
has been shown to be important in tumour surveillance in mice, it has also 
been associated with more rapid progression of HCC (N. Guerra et al. 2008; 
Sheppard et al. 2017). In humans it has been presumed that NKG2D ligand 
loss is a mechanism by which tumours can escape NKG2D-mediated 
surveillance by NK cells, although direct evidence for this is lacking (Mondelli 
2012; Zhang et al. 2015). There are also conflicting data on the relative 
effects of membrane bound and soluble NKG2D ligands, with some models 
showing a protective effect of membrane bound ligands (G. Liu et al. 2013), 
whereas others show a protective effect for soluble NKG2D ligands (Deng et 
al. 2015). Similarly, some clinical settings show NKG2D ligand expression on 
the tumour surface can be associated with poor prognosis (McGilvray et al. 
2010; Madjd et al. 2007).  
We are grateful that an ongoing collaboration with the hepatobiliary surgical 
team at the Royal Free Hospital affords us access to resected liver and 
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tumour tissue from HCC and colorectal cancer patients. By examination of 
the NK cell populations at the site of malignancy and in the host organ distant 
to the tumour, we aimed to understand the nature of NK cell functional 
impairment in HCC and CRC liver metastases, and whether NKG2D function 
is altered in tumour-infiltrating NK cells in these malignancies. We also 
sought to examine whether NK cell function can be improved through 
engagement or blockade of the NKG2D receptor, or whether NKG2D-
mediated NK cell function might be improved by other means. 
In this setting it is important to examine the relative contributions of liver 
resident and non-resident, liver-infiltrating NK cells. There is a wide variation 
in their proportions between individuals, from 10-90% of the intrahepatic NK 
cell population (Stegmann et al. 2016). Previous work on liver NK cells in 
tumours have considered bulk NK cells compared to peripheral NK cells (Cai 
et al. 2008). If there are differences in the way these two populations respond 
to the tumour environment this may have important consequences for 
potential NK cell-based therapies. 
4.2 Hypothesis and research questions 
Hypothesis: NK cells infiltrating HCC have reduced anti-tumour function due 
to interactions in the tumour microenvironment mediated by NKG2D/NKG2D 
ligands and NKG2D function can be improved by manipulation of the NKG2D 
pathway. 
1. Do NK cells infiltrating HCC resemble circulating or intrahepatic NK cells? 
2. Do tumour-infiltrating NK cells have altered NKG2D expression? 
3. Do tumour-infiltrating NK cells have altered effector function? 
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4. Does exposure to HCC in vitro alter NK cell NKG2D expression or effector 
function? 
5. Can NK cell effector function be protected from the effect of HCC by 
targeting the NKG2D pathway? 
6. Can other pathways be used to maintain NK cell effector function in the 





4.3.1 NK cells are prevalent but dysfunctional in human liver tumours 
ex-vivo 
Studies of the immune infiltrate of HCC have typically focused on CD8 T cells 
rather than NK cells, with reviews making statements such as “TILs in HCC 
tissues are mainly T cells” (Shirabe et al. 2010) or “CD8+ T cells represent 
the predominant population within the tumour-infiltrating lymphocytes” 
(Schmidt & Thimme 2016). In order to determine whether NK cells make up a 
substantial proportion of the immune infiltrate of liver tumours, we compared 
their frequency with those of NKT cells (CD3+ CD56+), CD8 T cells (CD3+ 
CD56- CD8+) and CD8 negative conventional T cells (CD3+ CD56- CD8-) in 
blood, healthy liver margins and HCC or colorectal metastases. Cells were 
identified by multiparameter flow cytometry of single cell suspensions derived 
from liver and tumour tissue as shown in Fig 4.1 A. In both the primary liver 
tumour hepatocellular carcinoma (HCC) and secondary liver tumours arising 
from colorectal cancer (CRC) NK cells were prevalent, accounting for around 
25% of the CD45+ lymphocytes, with a frequency intermediate between 
blood and liver. In both settings NK cell and CD8 T cell proportions were 
similar, with mean proportions of 21.5% and 19.1% for NK and CD8 T cells in 
HCC, and 27.0% and 19.6% for NK and CD8 T cells in CRC (Fig 4.1 B). In 
one example of blood, primary colonic adenocarcinoma, liver metastasis and 
liver tissue from a single patient, the composition of the CD45+ lymphocyte 
pool in the liver metastasis was more similar to that of the liver than to the 
peripheral blood or the primary tumour (Fig 4.1 C). 
In a paired analysis, NK cells in tumours comprised a slightly lower 
proportion of the CD45+ lymphocyte pool than in unaffected liver tissue (Fig 
4.2 A). However NK cells were detectable in all liver tumour infiltrates and 
constituted up to a maximum of 49% in HCC and 55% in CRC metastases. 




































































































Figure 4.1 Relative proportions of CD45+ cells in peripheral blood, liver tissue and 
primary and secondary liver tumours
A. Gating strategy for identification of intrahepatic/tumour infiltrating NK cells by flow cytome-
try, showing identification of CXCR6+ CD69+ liver resident NK cells (CD45+ CD56+ CD3- 
CD69+ CXCR6+).
B. Proportion of NK cells, NKT cells, CD8+ T cells, CD8- T cells in blood, liver and tumour 
tissue identified by flow cytometry in HCC (n=6) and CRC (n=10). Bars show mean and 
SEM, p values determined by MANOVA.
C. Flow cytometry dot plots showing CD45 positive lymphocytes divided into NK, NKT and 
conventional T cells (Tcon) for lymphocytes derived from peripheral blood, primary colonic 
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Figure 4.2 Liver resident NK cells infiltrate liver tumours
A. Total NK cells (CD56+ CD3-) as a proportion of CD45+ lymphocytes in HCC (n=9) and 
CRC (n=13) paired liver and tumour by flow cytometry.
B. CXCR6+ CD69+ NK cells as a proportion of total NK cells in blood, liver and tumour from 
HCC (n=10) and CRC (n=13) patients by flow cytometry.
Groups were compared using Mann-Whitney U test (unpaired) and Wilcoxon matched-pairs 
signed rank test (paired analyses). P ≤0.05 was considered to be significant for all tests. 
Figures are labelled: *, p ≤0.05; **, p ≤0.005; ***, p ≤0.001; ****, p ≤0.0001.
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resident population of NK cells that expresses CXCR6 and CD69 and is 
transcriptionally distinct from their circulating counterparts(Stegmann et al. 
2016) (Fig 4.1 A). We therefore asked whether tumour infiltrating NK cells 
contained any of the liver-resident CXCR6+CD69+ fraction. We found that 
both HCC and CRC metastases contained a high proportion of 
CXCR6+CD69+ NK cells compared to their very low frequencies in blood. 
Thus both HCC and CRC metastases had an NK cell composition that was 
more reflective of the surrounding liver tissue than the periphery, with a 
similar proportion of liver resident and liver-infiltrating (CXCR6-CD69-) NK 
cells to the surrounding healthy liver in colorectal metastases, and in HCC a 
proportion intermediate between that of blood and liver (Fig 4.2 B).  
Next we assessed levels of the major activating receptor NKG2D on tumour-
infiltrating NK cells as this is implicated in tumour surveillance. NKG2D 
ligands are known to be expressed on both HCC and CRC, where their 
presence is prognostic (Kamimura et al. 2012; McGilvray et al. 2009). Within 
individuals, NKG2D expression was reduced on tumour-infiltrating NK cells 
compared with NK cells in unaffected liver in both HCC (Fig 4.3 A) and CRC 
(Fig 4.3 B). Notably, NKG2D expression is higher on liver resident NK cells in 
liver tissue and both tumours (Fig 4.3 C). By contrast the expression of 
NKp46, an activatory receptor not known to be implicated in interactions with 
these tumours, was not altered on global NK cells from colorectal cancer 
metastases or primary hepatocellular carcinoma. There was no change in 
NKp46 expression by either the liver resident or non-resident populations in 
either tumour (Fig 4.4 A, B, C). There was also no change in the expression 
of the activation marker HLA-DR ex vivo on global NK cells or on either 
subset (Fig 4.5 A, B). In recent years there has been interest in so-called 
“adaptive” or “memory-like” NK cells, particularly with regard to intrahepatic 
NK cells, with this population believed to contain a memory NK pool marked 
by CXCR6 in some mouse models (Paust et al. 2010). In humans CD57+ 



























































































































































Figure 4.3 Tumour infiltrating NK cells show evidence of NKG2D downregulation
A. NKG2D expression by mean fluorescence intensity (MFI) on total NK cells, liver resident 
(CXCR6+ CD69+) and non-resident (CXCR6- CD69-) NK cells in HCC and paired liver 
(n=10) quantified by flow cytometry.
B. NKG2D expression by MFI on total NK cells, liver resident (CXCR6+ CD69+) and 
non-resident (CXCR6- CD69-) NK cells in CRC and paired liver (n=13) quantified by flow 
cytometry.
C. NKG2D expression by MFI on liver resident (CXCR6+ CD69+) and non-resident (CXCR6- 
CD69-) intrahepatic (n=23), HCC infiltrating (n=10) and CRC infiltrating (n=13) NK cells 
quantified by flow cytometry.
Groups were compared using Wilcoxon matched-pairs signed rank test. P ≤0.05 was consid-











































Figure 4.4 NKp46 expression is preserved on tumour-infiltrating NK cells
A. Example of NKp46 staining by flow cytometry, showing fluoresence minus-one (FMO) 
control and NKp46 stained peripheral blood NK cells. Mean fluorescence intensity (MFI) is 
shown for both conditions.
B. NKp46 expression as MFI on total NK cells, liver resident (CXCR6+ CD69+) and non-resi-
dent (CXCR6- CD69-) NK cells in HCC and paired liver (n=10) quantified by flow cytometry.
C. NKp46 expression as MFI on total NK cells, liver resident (CXCR6+ CD69+) and non-resi-
dent (CXCR6- CD69-) NK cells in CRC and paired liver (n=13) quantified by flow cytometry.
Groups were compared using Wilcoxon matched-pairs signed rank test. P ≤0.05 was consid-
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(Cerwenka & Lanier 2016), but have also been seen in response to other 
viral infections such as hantavirus (Björkström et al. 2011), and show strong 
responses to re-challenge. In both liver tissue and in the tumours, very few 
CD57+ NKG2C+ were seen, and where paired blood was available the 
proportion in the liver and tumour were not expanded compared to the 
peripheral blood (Fig 4.5 C, D). 
Having established that NK cells form a large part of the lymphocytic infiltrate 
in both primary and secondary tumours in the liver, and that they reflect the 
liver resident and liver-infiltrating population of NK cells, rather than the 
circulating fraction, we proceeded to consider whether these cells have anti-
tumour function. The phenotypes of NK cells infiltrating HCC and CRC were 
very similar, so these groups have been considered together. We assessed 
granzyme B and perforin as important cytotoxic mediators in NK cells. 
Perforin is required to form pores in the lipid bilayer of target cells and 
granzyme B enters via these pores to cleave caspases and induce apoptosis 
in the target cell. In line with our previous work, liver resident NK cells were 
granzyme B-low compared with peripheral blood NK cells or non-resident NK 
cells found in the liver (Stegmann et al. 2016) (Fig 4.6 A). Granzyme B 
expression was lower in liver NK cells than in peripheral blood, and there 
was a trend towards lower granzyme B in tumour NK cells than in peripheral 
blood NK cells (p=0.16 Fig 4.6 B). Granzyme B expression was lowest in 
liver-resident NK cells infiltrating tumour, suggesting that these cells have 
either completely degranulated in response to the tumour or are functionally 
exhausted. This difference was not seen between CXCR6- NK cells in the 
liver and tumour. This may be because these cells are present in the tissue 
only transiently before recirculating via the bloodstream. In a separate cohort 
of patients who underwent liver biopsy for HCC diagnosis, perforin 
expression was similarly reduced in tumour compared to paired blood, (Fig 
4.6 C). In keeping with the previous data, NKG2D expression was reduced in 





















































































































Figure 4.5 No increase in activated or memory-like NK cells infiltrating tumour
A. HLA-DR expression by flow cytometry on total NK cells, liver resident and non-resident 
NK cells in HCC and paired liver (n=10).
B. HLA-DR expression by flow cytometry on total NK cells, liver resident and non-resident 
NK cells in CRC and paired liver (n=13).
C. Representative example of flow cytometry do plot showing CD57+ NKG2C+ ex-vivo 
intrahepatic NK cells.
D. Summary data showing proportion of CD57+ NKG2C+ NK cells in ex-vivo blood (n=4), 
liver (n=8) and tumour (n=7).
Groups were compared using Wilcoxon matched-pairs signed rank test. P ≤0.05 was consid-





































































































Figure 4.6 Tumour-infiltrating NK cells are granzyme B and perforin-low
A. Representative example of granzyme B staining on intrahepatic NK cells, NK cells, liver 
resident and non-resident NK cells.
B. Granzyme B expression by flow cytometry, presented as MFI, on total NK cells in periph-
eral blood, liver and tumour on global NK cells, liver resident and non-resident NK cells.
C. Perforin expression by flow cytometry, presented as MFI, on total NK cells in paired 
peripheral blood and HCC biopsies on global NK cells.
D. NKG2D expression on CD56 bright and dim NK cells in paired peripheral blood and HCC 
biopsies (no paired liver tissue was available in these patients), showing that NK cells from 
tumour biopsies were similar to NK cells from tumour resections.
Groups were compared using Mann-Whitney U test (unpaired) and Wilcoxon matched-pairs 
signed rank test (paired analyses). P ≤0.05 was considered to be significant for all tests. 
Figures are labelled: *, p ≤0.05; **, p ≤0.005; ***, p ≤0.001; ****, p ≤0.0001.







































The anti-tumour properties of IFNγ are becoming increasingly recognised, 
and IFNγ knockout mice show accelerated DEN-induced HCC (Meng et al. 
2012; Parker et al. 2016). However, IFNγ may also contribute to a 
carcinogenic inflammatory milieu; in a mouse model of NASH, depletion of 
IFNγ producing intrahepatic CD4 T cells promoted carcinogenesis(Ma et al. 
2016). To assess the capacity of tumour-infiltrating NK cells to produce IFNγ 
we stimulated PBMC, liver and tumour infiltrating lymphocytes with IL-12 and 
IL-18 (Fig 4.7 A). Tumour-infiltrating NK cells produced the least IFNγ, in 
some cases showing a complete inability to respond to stimulation. 
Peripheral NK cells produced the most IFNγ in all cases (Fig 4.7 B, C). This 
confirms the impaired cytokine production seen in NK cells in other tumour 
settings (Platonova et al. 2011; Mamessier et al. 2011). There was very little 
difference in IFNγ production between liver resident and non-resident NK 
cells in both liver and tumour, with the inactivity in tumour infiltrating NK cells 
reflected in both populations (Fig 4.7 D). This may suggest that loss of 
activity is rapid and persists even after cells have been removed from the 
tumour microenvironment. 
We sought to understand whether the NK cell population inside the tumour 
was able to maintain itself or whether it requires a constant influx of NK cells 
from the surrounding liver tissue. To assess whether proliferation was 
impaired as well as function, tumour and liver lymphocytes were stained for 
the marker of proliferation, Ki67. Despite the reduced NK cell populations 
seen infiltrating tumours compared to in liver tissue, tumour-infiltrating NK 
cells express Ki67 at a similar frequency to their liver counterparts (Fig 4.8 A, 
B). Among non-resident NK cells within tumours there was a slight increase 
in Ki67 expression compared with the liver (Fig 4.8 C), possibly indicating an 
initial proliferation on first encountering tumour cells. This suggests that 
tumour-infiltrating NK cells are, at least partially, able to maintain themselves 







































































































Figure 4.7 Intrahepatic and tumour-infiltrating NK cells are poor
producers of interferon gamma
A. Representative example of intracellular cytokine staining for IFNγ by flow cytometry by 
total intrahepatic NK cells on stimulation with IL12 and IL18. 
B. Summary data showing intracellular IFNγ staining by flow cytometry by total NK cells from 
blood, liver and tumour, grouped by individual.
C. Summary data showing intracellular IFNγ staining by flow cytometry by total NK cells from 
paired blood, liver and tumour. Bars shown mean and SEM.
D. Intracellular IFNγ staining by flow cytometry by liver resident and non-resident NK cells 
from paired liver and tumour.
Groups were compared using Mann-Whitney U test (unpaired) and Wilcoxon matched-pairs 
signed rank test (paired analyses). P ≤0.05 was considered to be significant for all tests. 
















































































































Figure 4.8 Proliferation is maintained in tumour-infiltrating NK cells
A. Representative example of intranuclear Ki67 staining on intrahepatic NK cells by flow 
cytometry.
B. Summary data for Ki67 expression by flow cytometry on total NK cells from paired blood, 
liver and tumour. Bars shown mean and SEM.
C. Ki67 expression by liver resident and non-resident NK cells from paired liver and tumour 
(n=8). 
D. Example of gating of highest and lowest 25% of NK cells by NKG2D expression, and Ki67 
expression in these two groups.
E. Ki67 expression on the highest and lowest 25% of NK cells by NKG2D expression in liver 
and tumour (n=8).
Groups were compared using Mann-Whitney U test (unpaired) and Wilcoxon matched-pairs 
signed rank test (paired analyses). P ≤0.05 was considered to be significant for all tests. 




 and function.  
NKG2D ligands are found on both HCC and CRC, and NKG2D engagement 
on NK cells leads to NKG2D internalisation (Quatrini et al. 2015). To examine 
whether recent NK cell interactions with tumour cells might affect 
proliferation, Ki67 expression was compared on NKG2D-high NKG2D-low NK 
cells (gated on the highest and lowest 25% of NKG2D expression 
respectively). Ki67 expression was higher on the NKG2D-high NK cells than 
on the NKG2D-low NK cells. This suggests that NKG2D engagement, 
resulting in NKG2D internalisation, may impair NK cell proliferation in the liver 
(Fig 4.8 D, E). 
4.3.2 Functional inactivation of NK cells can be recapitulated by in 
vitro exposure to HCC 
To mimic the interaction between NK cells and liver tumours we used 
PLC/PRF/5 cells, an adherent line derived from HCC that expresses multiple 
ligands for NK cell receptors, including HLA class I and the NKG2D ligand 
MICA (Fig 4.9 A). Overall tumour-infiltrating NK cells resembled liver NK cells 
much more closely than peripheral NK cells, so NK cells isolated from liver 
tissue were used to examine the functional impairment in tumour-infiltrating 
NK cells. Magnetic beads were used to isolate NK cells by negative 
selection. Intrahepatic NK cells downregulated NKG2D on their cell surface 
on co-culture with PLC/PRF/5 (Fig 4.10 A,), an effect not seen consistently 
with peripheral NK cells. This downregulation was seen on both resident and 
non-resident NK cells (Fig 4.10 B). NK cells, either intrahepatic or from 
peripheral blood, co-cultured with HCC cells overnight do not upregulate the 
activation markers HLA-DR or CD25 (Fig 4.11 A, B). Instead there is a small 
but statistically significant reduction in HLA DR expression on intrahepatic NK 
cells following coculture. PLC/PRF/5 cells did not induce NK cells to 







HLA ABC HLA E
Figure 4.9 PLC/PRF/5 cells express ligands for NK cell receptors
A. Flow cytometric assessment of the expression of a range of ligands for NK cell receptors 
by PLC/PRF/5 cells. Expression of ligands for NKG2D (MICA/B, ULBP1-3), DNAM1 (Nec-
tin-2, PVR), KIR (HLA A, B, C) and NKG2A/C (HLA E) shown as histograms. Representative 


















































































Figure 4.10 PLC/PRF/5 cells induce NKG2D downregulation on
intrahepatic NK cells
A. NKG2D expression by flow cytometry and expressed as MFI by peripheral (n=8) and 
intrahepatic (n=17) NK cells following 18 hour co-culture with PLC/PRF/5 cells.
B. NKG2D expression by flow cytometry and expressed as MFI by liver resident and 
non-resident intrahepatic NK cells following 18 hour co-culture with PLC/PRF/5 cells (n=16).
PLC5, PLC/PRF/5 (Alexander) cells.
Groups were compared using Wilcoxon matched-pairs signed rank test. P ≤0.05 was consid-




NKp46 is maintained on coculture (Fig 4.11 D), and there is a small but 
consistent reduction in the proportion of liver resident NK cells recovered 
after coculture with HCC cells (Fig 4.11 E). NKG2D downregulation does not 
occur when NK cells are cultured in 50% PLC/PRF/5 culture supernatant or 
when NK cells and PLC/PRF/5 are separated by a transwell insert (Fig 4.12 
A), confirming the requirement for contact. This implies that NK cells are 
interacting with PLC/PRF/5 HCC cells via NKG2D-NKG2DL, a process which 
would be expected to lead to NKG2D internalisation and subsequent 
signalling via the ERK and AKT pathways. To investigate the fate of cell-
surface NKG2D we used imaging cytometry to visualise the cellular 
localisation of NKG2D molecules. NK cells co-cultured with PLC/PRF/5 
overnight internalise NKG2D (Fig 4.12 B, C), which accounts for the 
decreased cell surface expression. NKG2D internalisation is usually 
associated with ERK phosphorylation. In one example using intrahepatic NK 
cells, PLC/PRF/5 contact resulted in ERK activation that was greater than 
that induced by IL-15, which also signals via ERK (Horng et al. 2007; Jabri & 
Abadie 2015)(Fig 4.13 A, B). This implies another interaction at the 
immunological synapse or as a result of close contact with PLC/PRF/5 HCC 
cells, is impeding NK cell activation despite NKG2D signalling, and thereby 
preventing activation and cytotoxicity. 
In order to quantify changes to NKG2D cytotoxic function after contact with 
liver tumour, we used a two-stage challenge model (Fig 4.14 A). K562 cells 
do not express HLA class-I molecules and are spontaneously lysed by NK 
cells (Langhans et al. 2005). They express the NKG2D ligands MICA, MICB, 
ULBP1 and ULBP2 as well the adhesion molecule ICAM-1 (Boissel et al. 
2006). They may express low levels of ligands for NKp30 and NKp44 but 
blocking antibodies against these receptors, and against NKp46, do not 
affect K562 killing by NK cells (Byrd et al. 2007), whereas NKG2D blocking 
markedly impairs NK cell cytotoxicity against K562 cells, and in combination 














































































































Figure 4.11 Coculture with PLC/PRF/5 cells does not activate NK cells
A. HLA DR expression by flow cytometry on peripheral and intrahepatic NK cells following 18 
hour co-culture with PLC/PRF/5 cells (n=17).
B. CD25 expression by flow cytometry on peripheral and intrahepatic NK cells following 18 
hour co-culture with PLC/PRF/5 cells (n=10).
C. Representative example of CD107a staining by flow cytometry on intrahepatic NK cells 
following 18 hour coculture with PLC/PRF/5 cells.
D. NKp46 expression by flow cytometry, expressed as MFI, on intrahepatic NK cells follow-
ing 18 hour co-culture with PLC/PRF/5 cells (n=11).
E. Liver resident CXCR6+ CD69+ cells, identified by flow cytometry, as a percentage of total 
NK cells following 18 hour co-culture with PLC/PRF/5 cells (n=16).
Groups were compared using Wilcoxon matched-pairs signed rank test.  P ≤0.05 was 
considered to be significant for all tests. Figures are labelled: *, p ≤0.05; **, p ≤0.005; ***, p ≤






































































































Figure 4.12 NKG2D is internalised on contact with PLC/PRF/5 cells
A. NKG2D expression by intrahepatic NK cells following 18 hour co-culture with PLC/PRF/5 
cells separated by transwell (n=4) and with culture supernatant diluted 1:1 with fresh media 
(n=4). Groups compared by unpaired t-test with Welch’s correction.
B. Representative example showing NKG2D internalisation on NK cells following overnight 
coculture with PLC/PRF/5 cells by imaging cytometry.
C. Summary data showing internalisation of NKG2D following overnight coculture with 
PLC/PRF/5 cells. Internalisation score as computed by IDEAS software as described in 
Materials and Methods.
sn, supernatant.
P ≤0.05 was considered to be significant for all tests. Figures are labelled: *, p ≤0.05; **, p ≤




















PLC/PRF/5  MFI 566 
IL-15   MFI 486
Unstimulated  MFI 423
PLC/PRF/5  MFI 686 
IL-15   MFI 600
Unstimulated  MFI 503
PLC/PRF/5  MFI 507 
IL-15   MFI 432
Unstimulated  MFI 370
Figure 4.13 Coculture with PLC/PRF/5 cells induces ERK phosphorylation in NK cells
A. Representative example of flow cytometric staining of phospho-ERK in intrahepatic NK 
cells. Whole intrahepatic lymphocytes were incubated at 37°C with phorbol 12, 13 dibutyrate 
(PDBu) for 20 mins as a positive control or with PLC/PRF/5 cells for 5 mins or were unstimu-
lated.
B. Comparison of pERK staining by flow cytometry after 5 mins PLC/PRF/5 stimulation, 5 
mins 50ng/ml IL-15 stimulation and unstimulated whole intrahepatic, liver resident and non-
resident intrahepatic NK cells. Phospho-ERK MFIs are shown for each
condition.

















Figure 4.14 Experimental design to quantify NK cell cytotoxic potential after exposure 
to PLC/PRF/5 cells
A. Diagram showing experimental design of PLC/PRF/5 coculture followed by K562 
challenge.
B. Representative example of CD107a staining measured by flow cytometry on intrahepatic 




completely abrogated (X. Chen et al. 2007). After co-culture with PLC/PRF/5 
cells overnight, NK cells were washed off and challenged with K562 cells at 
1:1 ratio to assess ongoing cytotoxicity. Cytotoxic potential, as measured by 
CD107a expression, was consistently reduced following PLC/PRF/5 co-
culture in both peripheral and intrahepatic NK cells (Fig 4.14 B, 4.15 A). This 
effect is seen consistently in both resident and non-resident NK cell 
populations (Fig 4.15 B), although liver-resident NK cells have a lower level 
of baseline degranulation. IFNγ production is also significantly impaired after 
coculture with PLC/PRF/5 HCC cells (Fig 4.16 A), with the bulk of the decline 
seen in non-resident NK cells (Fig 4.16 B). There was a reduction in 
activation, measured by HLA-DR, on K562 challenge after PLC/PRF/5 
coculture (Fig 4.16 C), in keeping with an inhibitory effect of the HCC line. 
CD25 expression was unchanged (Fig 4.16 D). Similar impairment of 
degranulation was seen when isolated intrahepatic NK cells, stained with cell 
trace violet to distinguish them from tumour infiltrating NK cells, were 
cocultured overnight with a 5mm diameter slice of autologous HCC (Fig 4.17 
A). This suggests that the NK cell functional impairment caused by 
PLC/PRF/5 coculture is not caused by KIR-HLA mismatch or some other 
allogeneic effect but is a property of HCC itself. 
The reduction in degranulation is dependent on contact (Fig 4.18 A) but is not 
recovered by the blockade of NKG2D and DNAM1, either individually or in 
combination, suggesting NKG2D engagement is not the dominant 
mechanism by which cytotoxicity is impaired (Fig 4.18 B). Soluble NKG2D 
also did not prevent NKG2D downregulation on NK cells (Fig 4.18 C). 
Blockade of NKG2D using recombinant human ULBP1 or anti-MICA also had 
no effect on function (Fig 4.18 D).  
Cytotoxic dysfunction is maintained in the face of prevention of KIR 













































































































Figure 4.15 NK cell cytotoxicity is impaired following coculture with PLC/PRF/5 cells
A. Summary data showing CD107a expression measured by flow cytometry following K562 
challenge after PLC/PRF/5 coculture on peripheral (n=7) and intrahepatic NK cells (n=16).
B. Summary data showing CD107a expression measured by flow cytometry following K562 
challenge after PLC/PRF/5 coculture on liver resident and non-resident intrahepatic NK cells 
(n=14).
Groups were compared using Wilcoxon matched-pairs signed rank test. P ≤0.05 was consid-































































































































































Figure 4.16 PLC/PRF/5 cells impair NK cell cytokine production
A. Intracellular IFNγ staining by flow cytometry following K562 challenge after PLC/PRF/5 
coculture in intrahepatic NK cells (n=11).
B. Intracellular IFNγ staining by flow cytometry following K562 challenge after PLC/PRF/5 
coculture in liver resident and non-resident intrahepatic NK cells (n=11).
C. HLA DR expression by flow cytometry on peripheral (n=7) and intrahepatic (n=16) NK 
cells following K562 challenge after PLC/PRF/5 coculture.
D. CD25 expression by flow cytometry on peripheral (n=6) and intrahepatic (n=9) NK cells 
following K562 challenge after PLC/PRF/5 coculture.
Groups were compared using Wilcoxon matched-pairs signed rank test.  P ≤0.05 was 
considered to be significant for all tests. Figures are labelled: *, p ≤0.05; **, p ≤0.005; ***, p ≤











NK cells post autologous
tumour coculture










Figure 4.17 NK cell cytotoxicity is impaired following coculture with autologous 
tumour
A. Representative example of CD107a expression by flow cytometry on intrahepatic NK cells 
following 18 hour coculture with autologous HCC followed by challenge with K562 cells. 
Cells were gated on NK cells then cell trace violet positive to distinguish added intrahepatic 



































































































































































































Figure 4.18 NKG2D blockade does not prevent PLC/PRF/5 mediated NK cell functional 
inhibition
A. CD107a staining by flow cytometry following K562 challenge after co-culture with 
PLC/PRF/5 cells separated by transwell and with culture supernatant diluted 1:1 with fresh 
media.
B. CD107a staining by flow cytometry following K562 challenge after PLC/PRF/5
coculture with NKG2D and DNAM-1 blockade. Ex, explant; Perf, perfusate.
C. NKG2D expression by flow cytometry of peripheral and intrahepatic NK cells following 18 
hour co-culture with PLC/PRF/5 cells with and without soluble NKG2D.
D. CD107a staining by flow cytometry following K562 challenge after PLC/PRF/5
coculture with recombinant human ULBP1 and anti-MICA blocking antibody.
Groups were compared using unpaired t test with Welch’s correction (unpaired) and Wilcox-
on matched-pairs signed rank test (paired analyses). P ≤0.05 was considered to be signifi-
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Figure 4.19 PLC/PRF/5 mediated NK cell functional inhibition is
unaffected by HLA-ABC, IL6 or TGFβ blockade
A. CD107a staining by flow cytometry following K562 challenge after PLC/PRF/5 coculture 
with anti-HLA class I blocking antibody.
B. CD107a staining by flow cytometry following K562 challenge after PLC/PRF/5 coculture 
with anti-TGFβ receptor and anti-IL6 receptor blocking antibodies.
aHLA ABC, anti-HLA-A, B, C blocking antibody; aIL6R, anti-IL-6 receptor alpha blocking 
antibody; aTGFbR, anti-TGFβ receptor blocking antibody.
131
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blockade of TGFβ and IL-6 signalling; the former important in liver fibrosis, 
the latter an important driver of liver carcinogenesis and associated with 
impaired NK cell function; had no effect on CD107a expression after K562 
challenge (Fig 4.19 B).  
4.3.3 NK cell function can be restored by IL-15 
We sought to investigate mechanisms by which NK cell function might be 
restored. NK cells were removed from overnight PLC/PRF/5 coculture and 
rested in fresh medium overnight in the presence of different cytokines 
followed by challenge with K562 cells as before (Fig 4.20 A). Degranulation  
was improved by overnight treatment with IL-15 but not IL-2, IL-12 or IL-18 
before K562 challenge (Fig 4.20 B). In the same experiments IFNγ 
production was recovered by all the cytokines tested, but IL-15 showed the 
most pronounced recovery (Fig 4.20 C). IL-15 consistently restored 
degranulation and IFNγ production after PLC/PRF/5 coculture (Fig 4.21 A, B). 
In a stepwise comparison of NK cell function at baseline, after PLC/PRF/5 
coculture, after rest and after rest with IL-15, incubation overnight in fresh 
media alone did not restore NK cell function unless IL-15 was added (Fig 
4.21 C, D). IL-15 had only mild effects on NKG2D expression, instead 
functional recovery seemed to be associated in some cases with an increase 
in granzyme B (Fig 4.22 A, B). 
Added directly into coculture with intrahepatic NK cells and PLC/PRF/5 HCC 
cells, IL-15 did not induce degranulation (Fig 4.23 A). However IL-15 did 
have the capacity to recover the function of ex vivo tumour-infiltrating NK 
cells. Intrahepatic and tumour infiltrating lymphocytes from the same liver 
were incubated with IL-15 or media alone overnight and then challenged with 
K562. Unlike the intrahepatic NK cells, tumour-infiltrating NK cells were 
unable to respond to K562 cells unless they had been pre-stimulated with IL-
15 (Fig 4.23 B). IL-15 boosted degranulation of tumour-infiltrating NK cells to 
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higher than the basal level seen upon K562 challenge of NK cells from 


























































Figure 4.20 IL-15 restores NK cell function following PLC/PRF/5
coculture
A. Diagram showing experimental design of PLC/PRF/5 coculture followed by rest in fresh 
media and cytokine before K562 challenge.
B. CD107a staining by flow cytometry following K562 challenge after PLC/PRF/5 coculture 
then rest overnight in fresh media with the appropriate cytokine on intrahepatic NK cells from 
two individuals, one with NK cells isolated from a liver explant (Ex) and one with NK cells 
isolated from a liver perfusate (Perf).
C. Intracellular IFNγ staining by flow cytometry in intrahepatic NK cells following K562 
challenge after PLC/PRF/5 coculture then rest overnight in fresh media with the appropriate 
cytokine from two individuals, one with NK cells isolated from a liver explant (Ex) and one 



































































































































































Figure 4.21 IL-15 overcomes PLC/PRF/5 mediated functional inhibition
A. CD107a staining by flow cytometry of intrahepatic NK cells from liver explants and perfu-
sates following K562 challenge after coculture with and without PLC/PRF/5 cells, then rest 
with and without IL-15.
B. Intracellular interferon γ staining by flow cytometry of intrahepatic NK cells from liver 
explants and perfusates following K562 challenge after coculture with and without 
PLC/PRF/5 cells, then rest with and without IL-15.
C. Summary data showing CD107a staining following K562 challenge of intrahepatic NK 
cells unstimulated, after PLC/PRF/5 coculture, after PLC/PRF/5 coculture then rest in fresh 
media and after PLC/PRF/5 coculture then rest in IL-15 containing media (n=5).
D. Summary data showing intracellular interferon γ staining following K562 challenge of 
intrahepatic NK cells unstimulated, after PLC/PRF/5 coculture, after PLC/PRF/5 coculture 
then rest in fresh media and after PLC/PRF/5 coculture then rest in IL-15 containing media 
(n=5).
Ex, explant; Perf, perfusate.
Groups were compared using unpaired t test with Welch’s correction.  P ≤0.05 was consid-



























































Figure 4.22 IL-15 does not have consistent effects on NKG2D or Granzyme B expres-
sion
A. NKG2D expression on intrahepatic NK cells by flow cytometry, expressed as MFI, follow-
ing K562 challenge after coculture with and without PLC/PRF/5 cells, then rest with and 
without IL-15.
B. Granzyme B expression on intrahepatic NK cells by flow cytometry, expressed as MFI, 
following K562 challenge after coculture with and without PLC/PRF/5 cells, then rest with 
and without IL-15.






















Figure 4.23 IL-15 can restore function of tumour-infiltrating NK cells
A. Example of CD107a staining by flow cytometry on intrahepatic NK cells following over-
night PLC/PRF/5 coculture with IL-15.
B. Example of CD107a staining by flow cytometry on paired intrahepatic and tumour infiltrat-




It is generally considered that CD8 T cells are the most important lymphocyte 
population and the major anti-tumour effector cells in HCC. This concept 
appears to have arisen primarily from the work of Wada and 
colleagues(Wada et al. 1998), who showed in 1998 that a minority of HCC, 
less than 10%, have profound lymphocytic infiltration. In six of these tumours, 
which were all moderately differentiated, immunohistochemical staining 
showed 59% of CD45+ cells were CD8+, 46% were CD4+ and 7.5% were 
CD20+. These add up to well over 100%, implying no other lineages with 
significant populations, although no other markers were investigated. Many of 
the CD8+ cells in the Wada study will have been NKT or non-classical T 
cells, such as MAIT cells (Kurioka et al. 2016) or Gamma-delta T cells 
(Bouet-Toussaint et al. 2007; Hoh et al. 2012). Lymphocytes were seen 
infiltrating the other 90% of HCCs, but the separate populations were not 
enumerated. Based on these findings CD8 T cells have been the focus of 
HCC tumour immunology. Our results however show NK cells outnumbering 
CD8 T cells within liver tumours, suggesting an important role for these 
innate lymphocytes. Importantly NK cells have anti-tumour activity without a 
requirement for presentation of and specificity for tumour antigen or 
neoantigen, thereby offering a large pool of potential effectors. 
More recent work has demonstrated a significant NK cell population in HCC 
(Cai et al. 2008), as in healthy liver tissue (Doherty et al. 1999). Colorectal 
metastases to the liver are infiltrated by NK cells, in our study to a similar 
extent as HCC. In one recent publication, NK cell infiltration was associated 
with improved survival, although in another (smaller) series there was no 
association (Donadon et al. 2017; Pugh et al. 2014). By comparison 
colorectal primary tumours have few infiltrating NK cells in most cases 
(Papanikolaou et al. 2004; Halama et al. 2011). Our work suggests that the 
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importance of the NK cell infiltrate in colorectal metastases to the liver may 
have been underestimated. 
Recent work by our group and others has confirmed the presence of a liver-
resident NK cell population, transcriptionally distinct from peripheral blood NK 
cells and identified by the expression of CXCR6 and CD69 (Stegmann et al. 
2016). The presence of large numbers of CXCR6+ CD69+ NK cells 
infiltrating both HCC and CRC metastases suggests that the tumour 
infiltrating NK cells are predominantly derived from the liver rather than from 
the circulation. There appear to be slightly fewer liver-resident NK cells in 
HCC than in CRC, which may reflect the increased vascularity of this tumour 
(Abdullah et al. 2008; Ippolito et al. 2010). 
This study confirms the findings of Harmon et al that liver-resident NK cells 
are NKp46 high, NKG2D high, in keeping with the “immature” phenotype 
exhibited by these NK cells (Harmon et al. 2016; Stegmann et al. 2016). 
Although NKp46 expression is maintained in the tumour milieu, NKG2D 
expression is significantly reduced, which may be indicative of engagement 
with NKG2D ligands such as MICA or ULBP1 (Kamimura et al. 2012). The 
ligand for NKp46, recently identified as complement factor P (CFP) (Narni-
Mancinelli et al. 2017), is important in bacterial infection but has not been 
associated with tumours, which may explain the preservation of this receptor 
on the surface of NK cells. Despite evidence of NKG2D engagement, tumour 
infiltrating NK cells do not show evidence of activation as HLA-DR levels are 
unchanged. 
The comparative function of intrahepatic and tumour-infiltrating NK cells is 
little studied. Murine work suggests that colorectal liver metastases may 
activate the NLRP3 inflammasome and trigger NK cell-mediated killing of 
tumour cells via Fas-Fas (Dupaul-Chicoine et al. 2015). In humans Cai et al 
showed in a small series that global HCC-infiltrating NK cells contain reduced 
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Granzyme B and Perforin compared with global intrahepatic NK cells and 
showed reduced cytotoxicity (Cai et al. 2008). Recently Sun et al reported 
that NKG2A was upregulated in HCC-infiltrating NK cells in response to IL-10 
and that NKG2A and its ligand HLA-E were negative prognostic markers (C. 
Sun et al. 2017). However only 10% of tumour-infiltrating NK cells were 
NKG2A positive and the enrichment in tumours was predominantly in the 
CD56-dim NK cells. There was little change in the CD56-bright NK cells, of 
which the CXCR6+ CD69+ liver-resident NK cells are the major population. 
In our study we have sought to compare cytotoxic, cytokine-secreting and 
proliferative function in both liver-resident and non-resident NK cells from 
paired livers and tumours. Dividing the intrahepatic and tumour-infiltrating NK 
cells into liver-resident and non-resident, the difference in granzyme B is 
driven by the liver-resident fraction, with the non-resident cells having a 
consistently high expression. Non-resident, liver infiltrating NK cells are most 
similar to (and probably predominantly derived from) peripheral blood NK 
cells, which also have high levels of granzyme and perforin. 
Gamma interferon may have a range of anti-tumour functions, and although it 
has been difficult to bring it into clinical practice, this immune effector is an 
important marker of anti-tumour immune responses (Zaidi & Merlino 2011; 
Parker et al. 2016). Intracellular staining for IFNγ following stimulation with IL-
12 and IL-18 demonstrates a marked reduction in the potential for IFNγ 
production by tumour-infiltrating NK cells, down to almost zero in some 
examples. This is consistent with findings in other tumours, for example in 
breast cancer, where more aggressive tumours were associated with 
increasing impairment of cytokine production (Mamessier et al. 2011). The 
reductions we observed were similar in liver-resident and non-resident NK 
cells.  
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Tumour-infiltrating NK cells, both resident and non-resident, maintain their 
proliferative potential. That the impairment of function induced by the tumour 
does not also impair cell division overall is surprising. In both liver and 
tumour-infiltrating NK cells, there is a marked difference between the Ki67 
levels in NKG2D high and NKG2D low NK cells, despite no difference 
between resident and non-resident NK cells, which may suggest that recent 
NKG2D engagement, in the context of tumour, impairs proliferation as well as 
function. 
Different cytokines have been show to have different effects on NKG2D 
expression and proliferation. For example, IL-2, IL-7, IL-12 and IL-15 can 
upregulate NKG2D (Roberts et al. 2001; Y. P. Park et al. 2011; Lanier 2015), 
whereas TGFβ, IFNβ1 and IL21 can downregulate NKG2D (Castriconi et al. 
2003; Muntasell et al. 2010; Burgess et al. 2006). NK cell proliferation is 
promoted by IL-12 and IL-18, particularly in combination, and by IL-15 and IL-
21 (Lauwerys et al. 1999; Carson, Giri, Lindemann, Linett, Ahdieh, Paxton, 
Anderson, Eisenmann, Grabstein & Caligiuri 1994b; Parrish-Novak et al. 
2000). Given the maintenance of proliferation with reduced NKG2D 
expression seen in tumour-infiltrating NK cells, it is tempting to speculate that 
NK cells may be exposed to IL-21 in the tumour micro-environment. IL-21 
has been associated with liver damage in CHB and promotes tumour 
rejection via an NKG2D-dependent mechanism in certain murine cancer 
models (Q. Pan et al. 2014; Takaki et al. 2005). Its role in human HCC 
remains uncertain and should be the focus of future study. Alternatively the 
tumour environment may be dominated by a cytokine such as TGFβ, 
reducing NKG2D expression overall, with proliferation maintained by 
exposure of a proportion of NK cells to an upregulatory cytokine such as IL-
12 or transpresented IL-15, explaining why the proliferating NK cells also had 
the highest NKG2D expression. 
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In an HCC coculture system, intrahepatic NK cells downregulated NKG2D in 
a contact dependent manner, without evidence of activation, inducing a 
phenotype similar to that of tumour-infiltrating NK cells. We used PLC/PRF/5 
cells (a moderately differentiated HCC cell line previously known as 
Alexander cells (Daemer et al. 1980)) that express a range of ligands to allow 
interaction with NK cells as a model. There was a small but consistent 
reduction in the proportion of CXCR6+ NK cells recovered after co-culture 
with PLC/PRF/5 cells. This may suggest that the liver-resident NK cells are 
“stickier” due to adaptations to the tissue niche, such as expression of 
adhesion molecules. This may contribute to the potential potency of liver-
resident NK cells as anti-tumour effectors. Alternatively there may be a 
genuine loss of CXCR6+ CD69+ NK cells in the coculture due to cell death or 
alteration of the phenotype in culture. The reduction is similar to the modest 
reduction in liver-resident cells between liver and tumour tissue seen ex vivo. 
We took this as confirming the validity of the model, but could investigate the 
fate of CXCR6+ CD69+ NK cells further by sorting CXCR6+ NK cells and 
assessing their phenotype after co-culture with PLC/PRF/5 cells. We could 
also use CFSE or cell-trace violet to quantify cell division and adherence to 
PLC/PRF/5 cells in this system, but without an appropriate in vivo comparator 
the meaning of our findings would be uncertain. 
Visualisation of NKG2D by Imagestream demonstrated that surface NKG2D 
downregulation due to coculture with PLC/PRF/5 cells is due to 
internalisation of NKG2D. It is unclear why intrahepatic NK cells seem more 
susceptible to this downregulation than peripheral NK cells, especially as 
intrahepatic, non-resident NK cells show a small but consistent reduction in 
NKG2D surface expression. Work by Quatrini et al demonstrated the link 
between NKG2D internalisation and activatory signalling (Quatrini et al. 
2015). However in our system there is NKG2D internalisation without NK cell 
activation. To investigate this we used phospho-flow to assess downstream 
signalling. We were able to demonstrate ERK phosphorylation on PLC/PRF/5 
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engagement, suggesting either that NKG2D signalling is intact but is being 
over-ridden or negated downstream by an alternative pathway. 
To assess the possible effects of receptor alteration caused by PLC/PRF/5 
on NK cell function, NK cells were challenged with K562 cells and 
degranulation and cytokine production were quantified. Reductions in both 
cytotoxic potential and IFNγ production were consistent and marked. This 
functional impairment was contact dependent, but was not reversed by 
blocking NKG2D-NKG2DL interactions or DNAM-1. NKG2D interactions are 
important for degranulation in response to K562, so it is not possible to 
assess the effect of NKG2D blocking antibody in this system. These 
experiments could be improved by use of alternative cell lines as controls, for 
example using an HCC line that does not express NKG2D ligands to try to 
isolate the effects of this pathway, for example the KYN-2 cell line is poorly 
differentiated HCC and known to be ULBP1 negative and could be tested for 
other NKG2D ligands (Kamimura et al. 2012). Alternatively an insect line 
could be used to control for coculture in the presence of metabolically active 
cells without the expression of any ligands for any NK cell receptor (Barber et 
al. 2004). I would have liked to use PLC/PRF/5 cells with the NKG2D ligands 
knocked down with siRNA or knocked out using CRISPR-Cas9 or an 
alternative method to finally confirm that NKG2D ligand expression is not 
responsible for the functional impairment seen. This would be the cleanest 
test of the hypothesis that the NKG2D pathway is important in the loss of 
function by tumour-infiltrating NK cells. However blocking NKG2D-NKG2DL 
interactions by pre-incubating PLC/PRF/5 cells with soluble NKG2D only 
affected the slightest recovery of NKG2D expression, so it is likely that 
another mechanism is responsible for both NKG2D downregulation and 
functional impairment. The coculture system data is supported by the 
observation that intrahepatic NK cell cytotoxicity is impaired after overnight 
coculture with ex-vivo HCC tissue. It would be possible to characterise the 
NKG2D ligands and other NK receptor ligands expressed by the HCC in this 
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case from stored clinical specimens, and it may be that these markers 
influence the degree of functional impairment induced, but this data is not 
currently available.  
PLC/PRF/5 cells contain the HLA class I alleles A03:01, A33:03, B42:02 
(Bw6 group), B53:01 (Bw4 group), C04:01 (C2 group) and C17:01 (C2 
group), providing multiple ligands for KIR molecules of both the A and B 
haplotypes, so HLA blockade is important to demonstrate that inhibitory KIR 
are not the cause of lost NK cell function, and had no effect on degranulation. 
This is supported by one example of impaired NK cell degranulation after 
overnight culture with autologous HCC.  
TGFβ and IL-6 are cytokines associated with liver and HCC respectively 
(Dooley & Dijke 2011; Schmidt-Arras & Rose-John 2016), and both have 
been reported to impair NK cell function (Viel et al. 2016; Crane et al. 2010; 
Vredevoe et al. 2004; Cifaldi et al. 2015), so we investigated the effect of 
blocking these cytokines individually and in combination. However, consistent 
with the requirement for contact, there was no effect of blocking the IL-6 
receptor and/or TGFβ receptor II. In a sense this is unsurprising, as in HCC 
these cytokines are thought to be produced primarily by non-parenchymal 
cells such as Kupffer cells, for which there is no equivalent in our model. 
Rather than trying to inhibit the functional impairment induced by PLC/PRF/5 
coculture, we attempted to reverse the anergic state induced in the 
cocultured, tumour-infiltrating NK-like, NK cells. NK cells removed from 
coculture were washed and incubated in fresh medium containing a panel of 
cytokines. Only IL-15 was able to restore NK cell cytotoxic capacity. IFNγ 
production was recovered by varying amounts by all the cytokines tested, but 
IL-15 showed the most dramatic increase. Notably, overnight rest in fresh 
media did not restore degranulation or IFNγ production, suggesting that 
functional impairment was not due to a reversible metabolic restriction or 
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competition for nutrients in coculture. This recovery in degranulation and IFNγ 
production was consistent, recovering function even when coculture had 
rendered the NK cells almost totally anergic. 
Finally, we have demonstrated that ex vivo tumour-infiltrating NK cells can be 
re-activated by IL-15. This suggests that an IL-15 signal delivered into the 
tumour might activate tumour-infiltrating NK cells to kill tumour cells and 
control tumour growth and progression. IL-15 is being used to maintain ex 
vivo activated NK cells following infusion in the context of haematological 
malignancy and solid tumours in clinical trials (NCT01875601, 
NCT01385423) (Guillerey et al. 2016). Similar approaches with modified IL-
15/IL-15Rα complexes (IL-15 superantigen) are being developed for use in 
clinical trials (Rautela & Huntington 2017; Rosario et al. 2016). However 
administration of IL-15 and associated molecules can cause significant 
toxicity (Conlon et al. 2015), which appears in animal models to be related to 
systemic production of IFNγ by NK cells (Guo et al. 2015). IL-15 can be 
targeted to cancer cells by fusion with specific antibodies in order to enhance 
anti-tumour activity in animal models (B. Liu et al. 2016). It may be that a 
similar approach could be used in liver tumours to activate tumour-infiltrating 







Chapter 5 Conclusions 
We have shown that soluble ULBP1, which can be produced by HCC, is a 
marker of active CHB and also a prognostic marker in HBV-associated HCC 
in The Gambia. In the CHB setting, ULBP1 correlates significantly but weakly 
with HBV DNA viral load. This suggests that ULBP1 production may arise 
from a process several steps removed from HBV replication, such as 
hepatocyte clonal proliferation. This idea is supported by the presence of 
ULBP1 in HCC of other causes, demonstrating that other upstream 
processes that converge on HCC can also generate soluble ULBP1. We also 
find that ULBP1 levels may be of independent prognostic significance in 
HCC, suggesting that ULBP1 has a distinct biological relevance in this 
setting. 
A number of questions arise from these observations: 
1. What is the mechanism by which ULBP1 production is triggered in CHB 
and HCC? 
2. Can ULBP1 be used in clinical management of CHB, either as a marker of 
disease activity or as a tool for screening for HCC? 
3. Can ULBP1 be used in prognostication of early stage tumours as well as 
the very late stage patients seen in The Gambia. 
4. Is ULBP1 truly inert, or does it have a biological role in HCC? 
The mechanism by which ULBP1 is produced remains unclear. The serum 
concentration is associated weakly (possibly indirectly) with viral load but not 
ALT in CHB, and appears to be released by HCC of various aetiologies and 
also from primary human hepatocyte cultures irrespective of HBV infection. It 
may be a general property of hepatocyte stress; examination of ULBP1 levels 
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in a range of other liver diseases (autoimmune, toxic and ischaemic hepatitis, 
as well as acute viral infection) may shed light on this. Primary human 
hepatocyte cultures are the only in vitro system where we were able to see 
ULBP1 release. Manipulation of this system will allow us to test different 
stimuli for ULBP1 induction such as oxidative stress, translocation of 
bacterial products, DNA damage, to examine the dependence of ULBP1 
release on proteases as has been shown for MICA, and to investigate the 
dynamics of ULBP1 release. ULBP1 has been shown to have a short half 
life, which may contribute to the variation seen in the patient groups 
(Fernandez-Messina et al. 2016). 
In rich country settings, management of CHB is well established. Treatment 
is based on assessment of fibrosis, ALT and HBV viral load, which represent 
prior liver damage, ongoing hepatitis and ongoing viral replication 
respectively. Liver ultrasound is the first-line screening test for HCC. The 
safety and efficacy of the newer nucleos(t)ide drugs makes it tempting to 
consider treatment in patient groups where this has not traditionally been 
offered (Seto & Yuen 2016), although clinical trials will be required to support 
this idea, and current clinical guidelines remain unchanged (European 
Association for the Study of the Liver 2017). ULBP1, which tends to be lower 
in young individuals, might mark the beginnings of harmful liver pathology 
that would benefit from treatment. Long clinical trials would be required to 
establish this, but if ULBP1 is associated with abnormal hepatocyte clonal 
proliferation, which could be established relatively quickly, it might provide a 
simple, non-invasive way to monitor liver disease in the early stages of 
chronic infection. It may also be able to replace AFP in HCC screening, as 
ULBP1 appears to have a high specificity for HCC compared with other liver 
masses. 
In low-middle income countries, management of CHB is challenging because 
non-invasive assessment of fibrosis and quantitative HBV viral load 
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measurement are expensive and widely unavailable (Okonkwo & Onyekwere 
2016; Allain & Opare-Sem 2016). ULBP1 measurement could be used as an 
alternative to these tests to guide both treatment initiation and response. 
Currently ULBP1 concentration is measured by ELISA, requiring stocks of 
antibodies and a plate reader. However, if ULBP1 was shown to be a useful 
alternative to HBV DNA quantitation, a lateral flow assay could be developed 
or even incorporated into the current HBsAg point of care test for rapid 
clinical assessment. ULBP1 testing may not distinguish well between active 
CHB and early HCC, so depending on the setting liver ultrasound might still 
be desirable.  
Prognostication of late stage disease is an important proof of concept, but 
distinguishing between 20 day survival and 70 day survival is not necessarily 
very clinically useful, especially in a disease and setting where the 
possibilities for intervention are so limited. However, prognostication in early 
HCC, both in Africa and Europe, might be very useful. Having already tested 
the serum of 71 patients at the Royal Free Hospital it would be simple, with 
the appropriate research ethics approvals, to contact their GPs to ascertain 
dates of death to investigate whether serum ULBP1 is prognostic in a UK 
cohort of HCC of different causes. This may be confounded by treatment 
(sorafenib, TACE, radiofrequency ablation), but subgroup analysis, probably 
requiring an expanded cohort would be able to account for this. Similarly a 
larger investigation of ULBP1 levels in Gambian HCC patients (or in another 
patient group) would provide the statistical power required to definitively 
answer the question of whether ULBP1 provides independent prognostic 
information that is not captured by markers such as bilirubin and albumin. 
Because of the co-variation of these parameters, a cohort larger than the 
Prolifica HC4 cohort may be required to establish this. 
It appears that soluble ULBP1 is predominantly present as soluble protein 
and does not cause NKG2D internalisation. However presumably ULBP1 is 
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released from HCC cells, where it is expressed on the cell surface(Kamimura 
et al. 2012). It is still unclear whether this has a direct effect on tumour-
infiltrating NK cells. I wanted to compare NKG2D expression between 
tumour-infiltrating and intrahepatic NK cells between ULBP1 expressing and 
ULBP1 negative tumours. Although NKG2D MFI is consistently reduced on 
tumour-infiltrating NK cells, in some tumours NKG2D expression is markedly 
reduced, and it may be that this is a direct result of interaction with HCC via 
ULBP1. It is possible to stain HCC for ULBP1 by immunohistochemistry (Fig 
5.1), however most HCCs are ULBP1 positive, so intrahepatic and tumour-
infiltrating NK cells must be analysed from a large cohort of HCC patients to 
answer this question. 
The functional impairment of NK cells in tumours has been observed in a 
number of settings, and is believed to be a product of the tumour 
environment, as in certain haematological malignancies comprising individual 
cells, particularly AML, NK cells can retain activity and have demonstrated 
clinical effectiveness. We have developed a model system using human cells 
that recapitulates the inactivation seen in ex vivo HCC-infiltrating NK cells 
and allows for examination of the mechanisms of this inactivation and the 
testing of methods of reversal of NK cell functional impairment. 
The mechanism of NK cell anergy remains unclear, and may be multi-
factorial. It is a contact dependent process, which results in durable inhibition 
of degranulation and cytokine production, which affects both liver resident 
and non-resident intrahepatic NK cells and can be reversed or overcome by 
the administration of IL-15. It is difficult to guess what this process might be, 
and an unbiased tool such as transcriptomic or proteomic comparison of 
unstimulated and PLC/PRF/5 exposed NK cells (or ex vivo, FACS sorted 
intrahepatic and tumour infiltrating NK cells) would be useful to examine the 
changes induced by the tumour environment. Recent attempts to apply  
AFigure 5.1 Immunohistochemistry of ULBP1 
A. ULBP1 staining by immunohistochemistry of two colorectal metastases, showing low and 
high ULBP1 expression.







transcriptomics to HCC using unsorted cells suggested IL-10 expression by 
Tregs might contribute to NK cell anergy, but did not suggest a mechanism 
by which NK cells can be directly inhibited by HCC (Chew et al. 2017). 
Sorted NK cells might provide cleaner data to examine this question. 
Proteomic analysis of CD8 T cells has shown that that transcript copy 
number does not necessarily equate to protein content (Hukelmann et al. 
2016), and we might expect NK cells to behave similarly (Bezman et al. 
2012). However several million cells are required for this methodology, which 
may be impractical (by magnetic beads I was able to isolate at most 4 million 
intrahepatic NK cells and 2 million tumour-infiltrating NK cells from a single 
explant). 
In the absence of a mechanistic explanation for the NK cell anergy seen, the 
recovery of function with IL-15 has potential clinical applications. Systemic 
administration of IL-15 is toxic (Conlon et al. 2015), but lower doses, either of 
IL-15 or IL-15/IL-15Rα superantigen to mimic transpresentation, might be 
administered intravascularly, directly into the tumour in a manner similar to 
TACE. To enhance antitumour activity, a bi- or tri-specific protein that is able 
to induce an immunological synapse between NK cells and HCC targets and 
also contain IL-15 activity might activate endogenous NK cells to generate a 
persistent anti-tumour response. Such a strategy has been tested in a mouse 
model of leukaemia (Vallera et al. 2016). This example used CD16 to target 
IL-15 to NK cells, but as liver-resident NK cells are CD16 low/negative, 
alternative markers such as NKG2D, or NKp46, which is high on liver 
resident NK cells and maintained in the tumour environment, might be used. 
NKG2D ligands are probably not specific enough for targeting activated NK 
cells to tumour, instead a specific, cell surface expressed marker of HCC 
must be used. Many of the promising HCC-specific tumour markers are 
intracellular proteins (NY-ESO, MAGE-1), but a molecule such as glypican 3 
might be a potential target (Shirakawa et al. 2009), or in certain 
circumstances HBsAg could potentially be used (Bohne et al. 2008; Krebs et 
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al. 2013). Our culture system with ex vivo intrahepatic NK cells, whose anti-
tumour responses may be different to and more biologically relevant than 
those of circulating NK cells, might be a good platform in which to screen 
candidate therapeutics before progressing to animal models or clinical trials. 
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